var title_f37_12_38080="Right winged scapula";
var content_f37_12_38080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Right winged scapula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38080=[""].join("\n");
var outline_f37_12_38080=null;
var title_f37_12_38081="Chlorophyll: Drug information";
var content_f37_12_38081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorophyll: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nullo&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Control of odors:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 100-200 mg/day in divided doses; may increase to 300 mg/day if odor is not controlled (maximum: 300 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ostomy: Tablet: May also place 1-2 tablets in empty pouch each time it is reused or changed.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Control of odors: Oral: Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nullo&reg;: Chlorophyllin copper complex 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Control fecal odors in colostomy or ileostomy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Gastrointestinal: Diarrhea, green stools, abdominal cramping",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Reduce the dose if cramps or diarrhea occur; if symptoms persist, consult healthcare provider. Smallest effective dose should be used.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (ChlorOxygen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (10): $2.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Derifil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $46.00",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8857 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-B6E796A386-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38081=[""].join("\n");
var outline_f37_12_38081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149663\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149672\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149664\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149669\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149665\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149659\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149651\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149660\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149670\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149654\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299019\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219124\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323058\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8857\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8857|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_12_38082="3D ultrasound of normal fetal face";
var content_f37_12_38082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81141%7EOBGYN%2F77964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81141%7EOBGYN%2F77964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal face and lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rendered 3-dimensional image of a second trimester fetal face. The image demonstrates normal nose and lips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    3D-ultrasound of complete cleft lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rendered 3-dimensional image of an early second trimester fetal face. The image demonstrates a unilateral complete cleft lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38082=[""].join("\n");
var outline_f37_12_38082=null;
var title_f37_12_38083="Splenic injury on computed tomography of the abdomen";
var content_f37_12_38083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Splenic injury on computed tomography of the abdomen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 397px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGNAfQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UpaSigAooooAKKKKAFopKKAHBiCPam0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSjmkooAKKWkoAKKKKAFpKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiloASilpKACiiigAoopwXKk56dqAG0UUUAFFFFABRS0lABRS5pKACip7e2knYCNevet7TPDLXDDz5NnGeKAOapQCeld3H4aso13ffC4yCe9aUegQiMhYVBPIAoA80EbnorflTvIl/55t+VemwaOwkH+jMx6cL3prWZ2yE2zoQcZZOKAPNPIlwD5b8+1IYZB1jYY9q9S+x28cSMqqcHGCOc0z7DGBvKqyF8EY60AeXFGHVSPwptep3mmWkVyu+NfLkHQjpVGx8GzazefZ9JsZb6UnhbdCxx+HSgDzqium8aeDdc8JXSJrul3OnpNkw+cuN4Hoa1Ph74F1nxVbXdxpGlT3sduP3jIuQvsPU+woA4Wiu9Phu1KSEoyvGSjowIZSOoI7VUbw1AHKjkHkfSgDjaK7eHQbYADy/nz/Ee1Xf7KsxHtCL5vXAGc0AeeYowfQ16SNJskQMYgSx6Beall0e0WFmVFBz/ABDtQB5hRXo3/CP2spxIig4zxVaTwzZuQNhBx2OKAOCorrp/C8JVvLmKv2BOazpfDV4ELRbHA564NAGFRVie0ntziaJ0+oqvQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUtJRQAUUUUAFFFFABTwwCMOcnFMooAKKKKAF4oop8MMk8gSJSzE4AFAEdSwW8s7Yijdz7Cum0fws8hEl9lV6bB1rt9M0r7Ncxx2Vszo64IRckGgDgLPwvPJAJp38tScY71qxeFLZTGxkZgV3c8V6ha/DTxFrE6OxS0tCwwx6sPpXeaT8JdHtFQ3lxcXUq+p2g/hQB4CnhyPYDDvKL6Co7m5GmQYjt5GkPGSD0r6zsNB0ixiCW9lFtTrlc815j8aRpGnWKyfZEM0p/dhFxjFAHg0N7fyM7W8EoVjk7l6V2vw81A3mswR3joVY7SHPP4VwbanrNw8kdoXjib5do9PSl0/TtWtZ0uEkKOOQc0AfX9rp1vZ24nt7NJHHUEAlzUw061vLNxe2UUUe3cFIHB714V4Z+K2v6bLDDqLR3MS8btvOKteMPjBe3EbwaRbsWYf6wrgZ9hQBxPxPvDp/iW5TTsCFGwAOlcyPFMwgVWXLDnI9arX8esaxdPPcRSSO5z0qBfD+pMM/Z2A9TQBYvvFGoXabC4VMY4r2z9nz40eH/BOh3eleI7O4jeSXzheW0YcvkAbWGQeO2K8Nbw9fLHuaMD2zzUcui3cYUsFwfegD0f47/E8fEbX4ZbGNotHsAVtopR8zkkbnb3OBx2FdH8IPj1beCdIOl3mihrYkvvtztYt7+teFSW08J+aNufQUiWdy4ykEhHstAHa/ED4gP4n8X3ms21pHZC4YExxDGccZPqT3NR2WviYGSTJwvbjHtXHGzuR1gk/wC+TSxLPC5Gx1J6gigDudLmGtavbQSSeRHI4AJr6R0Twloun2aPbWKSuVALvySa+U/DP2r7ckiAZiO4bq9t0v4gX9jp8QuQkhUZ5HJoA9OupNN8Oxf2odOtt1uuR5kY5r5d8e+OJtd8TX13bQRWyyyHakC7VArp/GnirXPEkhjmby7Ag4SM15WLa4tLrMkGcGgD0TwPoWueIJgvCRuOZG44r0NPhLczSoW1Fk7cDINZ/wAEtXLxyW92AnIIyOTXtU++VESGTYRy3HX6UAeLXfwh1eK5ElleRSqTgqwrO1TwbrujbnubLzYx3i6GvZpbvU4r1gkaNAOdxPNQPfTv5iX1xCsBUnJ7D0oA+eLxcErcRhA4+6y1kXnh21uFbYpSYDPycfpXp3iuTRLiRhb3unZTgI8gUn6V5rJBqOn6gZvKMlvJ82VYMMfhQBx11ptzAx/dOydmAqkRjrXrEWoxy2zQlFVm5BK9KxdS0Gzv1YxuI7gnjHT8aAOAorRv9IurNn3JvRT95eRWf0oASiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqSCGSeQRwoXc9AKAI6kihklYLGjMT6CvSvCHwn17W9Pa/t9NnuIU68bVB+p616j4Q+Ec8YV9WSOI9fKTt+NAHgul+FrmbbJeK0MR6ccmuv0jQjEyxWFk8zFh86Ln86+gD4O0iyiIvkUqqYXd/FXE6p45s9Eka00Szih28/d60AVfDXgi+v5ZJb7/AEZImA2dzn2r13RdE07SLeJoUjV1Gd7dTXhF14u1+/vWn04NaylfmGflIrPvbzxJMNlzqrxRv1UN0oA+l7vUYLS0EjTImP8AaGKwtQ8c6BZqq3GpW+cEja2SCK+c2tpJYAbvVZpiG5UyHAqK8ttHtmDREyjb8wc5IagD2LWvi7pUkTxaZHJNKB1xjJrzXxBrOpeKpGVLfCqANr9vcVix6vbW9s8cVsEckYbFMl1u7mA8vKZ4DIOaANCDTTGI4roxx7DlscGr902nJH8rqTGdpJ5z71h2+navqcy/u52JOMkHmu60b4UahMySagfLgfrzk0Aculxp3kyoYg0ucqypnIq1Akk1sTBpTsSNo+XnPrXr2k+BdN0+URi2SRY1yu89TWyunwKQiJEgU56fe9qAPD7Lw3rFw0SrAYFA4J711WkeAriNUe/nBY5OB0Ar0E2ztO0vkqjA7VLHgCnIyfalWUsZNu0gfdoA42LwXp8xBm3kbSuAKt2PhLRDamP7Esiqxy5+8B9a6lUjy0QkO/cTx6VStWjjvJIkOV75oAyF8J6QLYs1pAdnIO3qPQ1a0/RtMjcrHYwnfhcbRkCtO3SIRrIfu7ioXPWpZGFuDkZYnsKAMe+0Wzyym2hEJbBG0fKfWszU/DulTwyCa0idmQLvCjIx3rdaQzKzf8tQ+MEYyKjDASNC5wuCBkdPagDjl8E6b5yvDEwUkA46UzUPB1wYleziwSSApOeK7dYQojhZtqKcgetaNvFM0SOzFNhyMngigDwy78N3dpIGnTO4kYB6VkS6SJPnZGGCcivoVtMtpYWuJfLck4HHSoI9Js5fMAiiC7cHKj86APCLf7bA8Q02Rk9SBXRWvjXX7BXAMTlMBWfmvRby30bTLCQJDb7yv32OCK8O8TalFb38qQzrGp4A9vagDrJviH4hkkKbYA7jBIHauA8VXPiTVLhlmvGK/wBxXwKzJfFH2f5Y3aWQcbgOlVT4iMsqNIzqo6jGc0AZNzpV/GvmSwOQTjd1qsDcQZwZY/XGRXoS61DLYGYNbmNRgguM/lSwXNteWjiW3VlYffoA4CPULqNgfOc47Mc1t2GtozDdiCTHLdVNaLeFLa7iV7N2Qnru7H6Vzmq6HeabKVljLL1DKMigDvrG4jeJfOVSpXJYdGFZ+raDY3ufs6+TJ13AcYrjLDVLmz+WNyY88qeRXVr4jhuo08v93OAAcigDmNS0e5smJK74+zLWbXbR3V2bjyNplSQ52betaepeArhrD7W9rLBv+7uXAoA81oq9qWm3GnzNHOhGO+Ko0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVvTrCa+m2QqSByT6UAGn2M17LsiXIHU+lfQHwF+FKa/qq3t8jLplmQ0zEf65uyA/z9q4zwh4akubi2s9Nj3zzkR89ya+ydF0aPw54esNBshmUrmVk4LN/EaAN67t2h0k2+mRpGqrtREGAB6CuL1Yvp9oZ71Tb+nmHhq7DWdZ0/w7pf2vV7lLeBBgE9WPoB3NfMPxc+LMniC5FraxmLS42PlqPvOf7zH+lAFrx/4m/tFo2VlRYuMK2DivMrzV4gSYIkl2nDFhyKxpdSluHcu52kZFQdM4B5GfrQBcuNWuZZ3dZSnGAB6VXlurl2w8zPkcGoEDrEVwCegNaWk6ReanMiWcTySLwwC5xmgDPWR9pJHzZ6mrVjYXd/KiW8LuZPvADvXqeifC51jS7v33x4y0S9a73RtC02wESWMaqHBGSO/uaAPLdG+G13NLEmojyowc8nFd9p3gvSNIiXFsk02ckPzW9eeZ9nlLDcyPwp7/SpraFbpFkV8PH2J70AJFJaiMJGgjk/hG3Aq812yWToc715b3FZ0cyzyTRuV+XqxGcVLcFkfMcyujY4xyKALEpaeNZrbakrDG0t90etZ0k4jlCzyo0SAsZB61K07WmRcnespzkDp7GolVWgm3pkFs4A7UAWIJVkgiQzq4Y/KAe1VNTtzaX3nQhzn7wzkCq8aObyQXCsgUBo2UZwKsC8kfMkKkrt5HrQA+GKS5g+1wEKYjhge9UbqIR6nA8ZLpK3I9KmS6e5dwCEgYbdoGM8VBIiwSxS5OwEBSDzmgCW+TErCA7ZVbCqOhrRghZoopS4aTb8ydxV5NDW+u7e7VyrFcsRxilvxBZQz7W3XKDIOaAFgtYrjT5WXYt24yAOxrmQuGkDvlyfn69qmsdQmgubO6UM8M0m2Xaeme/0p+pW7R3UsaKWBO/erdjQBFao01wIyWaRm4Y9h2q7dxzNNLHMSqQcAjo1FpJHbytOqs0kajZg5FTy3ElxYSTT4QlshOoxQBnxXMdtDtuN3lgfKfU+lcF4i8Xy208z2+1EYYO44CgVH4y8TyxG6xIFitRy5HAzXg2u69c6pK4LsIT2/vfWgC/4i8XX2oTSJFMwizjdk5IrmHdnYs7FmPUk5NNooAKKKKACrllqNzZ8QSkL/dPI/KqdFAHWaX4sNtHiSIhz1ZOQfwrsNN1W11qFIpCjMwEe7oMemK8jqxaXU1sxMEjJu64NAHrOrfDbTZHY2d6iMib3UMM59q4HVfC2p6URMsRliB4ZBn86yTql95u/7TLu+tdh4f8AiFdWcQg1KJLmPI+cj5sehoA9X/ZX0bTdf8Q3N9e7Wu7GMH7O/ucbsV9S3+n2E48m4toXRuqsoxXx34K1iG11o+I/DtxHaX0Zz5WflkH8St7Gvq/wV4nsfGmhJeWw8q4A2zQE/NE39R6GgDy74t/Bq1u9PmvtBhLlQXe2xk49V9fpXyZ4h8O3GmyuUUtED6dK/QxdUm0y6MWqYWBmxHIOw968h+PPw/X7O/iHQYA0MjZvYk5Az/y0Ht6/nQB8Y0V0/iHQTC7zWoJQH5hjpXMkYODQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU+KNpZAkYJY9hQBLZWzXVwsa8ZPJPavSdD0qO1tI/LAcnO4Y5+tV/DelQWFtE8wBdz83GcfWte5uUso2dDGgRs7j39qAPoT9n7wdHZWb65cAmWUFIUdfu+rCut8b+OtF8E2s7tNHd6q3Hl+ZyD/tf3R7V836d8Ttdl0trY3jWlmo2r5fykj2PauD1jU5bu+eSdndZMnOeT9fWgDpvHHjrV/EmoSXVzdNKhPyqOFQegHYVxp/fbmLHK9j3ogXIZkIHHIJpFURyOHzhu/agBhjAywPbFSWwdv3SozFjwF6mr+maVLqE/lWqPIW9BmvaPA3g3TNKtYbq6BnugQxyvEf4UAcf4S+Hk2peVNqbfZ4SchSPmIr1vRtKs9FtlmsoEQ52MUHOPc1oLs8k85Rs7arLbyxwjyZFKBuVagCach33whwxwHVTxiopYUlfEcmCoG5P8KrPN9kF1uLKpxnB6e9WIGF0wLLHD8o2y5+9QBFK86rI0TbyFOMfyqAXyMmyNwry4CgjkNU080cLBXkWKXBIJ6MabpirJKJjhjnkgdKALlpZxNIBDtMwOX561Su2jSY+YfKuuoB6Y9KsCC6h1Pz4Bv2gtjpRKq3kbST2+ZSRz/d9xQAkuGgAaNlnZPlUjIaq0RmjlMrSAYXa8R9famW+prFrJt5pd5RcxqeCa1LlVKC4lcNjllYYODQBBthZTI7nYqnODWSkxhmKRN5e4EgH0rTVYZuXBCdVAPH41Oul3CX8b+T58cy4DKM7KAKWiv9ojMFyNrYJXb1qpJaSmeQwRSM6PwrDOR7V2ui+CLlZklnl2Qnnb/FXWR2OnWBQgJu9W70Ac9o1lcnRWkkUxSbcLu7Vw2o208F7M00hIztYHvXrt9qVskLCaPcnYDoa4LX7iKe7EhhCjZng/lQBz6JbwxuoiMaoflU+tThGnCGOQeUy/MT2p9rpz3UZlcttLfNzzitFRAIRDDE+VONuc0AZcfkwLJDE4wzDkdc+1Ra3LDDYSMHYvjkeoqDWb6LSiZpYAqEbjz6eleX+OfHBXQ5r/AE9nDSMYYw3Y460AeTeOtTe81y6CTl4i2SAeCa5mnOxd2ZjlicknvTaACiiigAooooAKKKKAClHUY60lWdOC/b7feMrvBI9s0AR3ClJWBXafQ1FWhrRRr12TOCTWfQBe0nU59MuPNt2/3lPQ17J4I8Zy2F1aapp12YLmP7yL0b1Vh3Brw2remXslhdJNGTgHlexoA/QPwp4v0T4g6YbK4Agv9uXtmbDf7yHuK6XRtMm02KSymkF1YOCEDjlR3UjuK+LvD/iCNxDf2O9LuI5QqcFTXvngb4ymSKO08SRfv8ALcIPvH3FAHB/GbwRH4U1cG0T/AIll8S8GefLP8Sfh29q8L8RaHvje6tkwF6j1r7A+KGpWXinwbcWymMyxnzo3U5Kken1FfNWVl3xAAAdiKAPJyMHB60ldJ4s0g2s5ngU+U3JwOBXN0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXX+C9LZZxe3KERj7uRwR61keGLJL3UlSYDyhyxPavSWcwwRRRjfEi7QvtQAl8wiZZLYo8O3LMOg9jWU1udXYSygR6fGeg43Gr1vAtsXUH9xgl1Jzn2rPvL0TKiWqeVEudoB4zQBWv5d84RAogHCr6CoWC+WEZW6cEUvmLJ88mN+OakUHzAQA24cZoAiWMxxq3BB7j+tb/hnw9c+INRSGNdkBPzyEcL71qeDPBt9rlwsskTx6cpBdjxn6V7rpVtpllbxwQ2/lRKOW29SKAMzwroFjoUSwWoSQ7fmdhya2mKt5hEeF25IHU1CyRiZniJ2c9eMUlu7+UVlkUSNyhA6igCrNK2yFrfcV+6Rnp9aZGW+1Kj7wiNksOjVLpUiPclbuF9of7w+XPvWhfQGCVWjZRG0m7YecCgBl06XEEyxlS2MENjJrPURtaiB+Wzkru6VoXFqJpXeOJgxHUcdOlZt6HJjk2gNEcOFGT9TQBr39hbXtvA+FaZADlT09qz7OS5jkliuU8hcHYy8g/Wt/QLO3g1BpftKLazKMhh/F3rqLi00iV1SRoguOxHNAHnEweIiWOSRpAmScnBFP+0weX9oiaQJgAhugr0CXw/YSW4S3lADA8k9BXPat4Ylt4mCOJUyDtHYUAeI/E69vrK9iuraTEqDKSKMfgan8IfFmzv7ZbbW4ljvchRIBw31q1r/hDXrvxHIfKaTSlBcMxyPpWHD4M02x1e0k1eMJA7HcF4I9KAPevDmmQ61bwziHbG+DgenrXeWNtZ6dC0cbKFXk7u1eKaP4xm0zWbLSdF2zWbfIJWOdoFXNf1/VdT1nyLcPa2aNtd248w+3tQB6Hqvii1hBUzDdzsQdWrg7rWtR1K5dJQscAztKHnH+NZUlvFDfjz5ma4AwoY8Ae1XdOhuI7xDCw8pm+fjP4UAanhnV0t2nsb9nmCcoznJqneTBZ7gthiDlMHt6VY1e0iiVbm3t23kncQKiS1H2VXcJtxuOOooAsAzSorRssOF3BcfeqDToZY5PPk4cklueKs7muIR8oBQYG01ga3rS6boktxdHyxESpVv4vpQB598Z/E4itFtVwsobBUH9a8g8S3z3vh2EINqJMGcepwQDVPxzrbazrU04J2E8DNJvd/CErlhtEqoQR170Ac3RRRQAtJS0lABRRRQAUUUUAFW9OZY5jM+NqDv6mr3hzQZ9akmKMI7eBd0sh7egA7k0zW7KLTysCSbmJyc9aAKV9KksoMYOMfrVailAycCgBKKUgikoA0tH1a40yQmFv3bfeXFerabMbrSoLmE4Dc7j1Brxeus8PeKRZW8dpcRAwg/eHagDub64vo/39rcOpAG75jh/wqrJdxi3juFi+cnExP8AOp3mS7ijmtgXj6cciorizSNGKHczjDDPT3oAj1BIb20aFx1GR7CvM9Vs2srpoz93+E12en3ElvfNFeMwGcA1D4tsjNZNOFyUOQR6UAcLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSqCSABk0ld98IPBk/jHxRbWEKEhzlmxwiDqx9qAE8N6BdJYLMoO6U9AOlbzyLZxxxyOBIx4THWvsTw38OPD2h2sCRWgmljQIZH/i98V83fG/Q7e0+K2oyRYtrWGGJo1A+UsVycUAcbq13AIUgh3LMPvnHBNYwYbcnaWH8PTNNuZGM7Ox3NnJbNMZN+5k+bufWgBJt4+ZYsIODXW+A/B0viO7/eSiC2Qg+YR+lZ3hTQr3WtTjhCSG0Jy8gHCivobRdJstNtIILIeVGByp/iPrmgB+gQPoUC2MirJbKNquB/Or8lukzPNHICCMbPSqYuSPMDMzRR5yGHeo2bE6NZyI6tgkZ4WgCFPLcmO4d4yjFenrU8MMgZY0YPEoAIzyD61HdS3C/vJUVlZun9aJIhJcLcWrGEDG5B/F9aAIzs2TLcS7snCP0IoZLi38oyklCQMippbKG6bMabsc46jNQNdXDJHDcxFlDbW28baALdzJOXWZZF2qMPg9qhu0Ez/arN3Nxty6Z+8PpT/7PktpS4DGLHOTmnRytAQ33RIMAnigCqmVgDHcI5DyoHQ1aszDqfmJbNI01t94881YhWGXestwocEBR0xTbSKK2mkFmrJcq2XYdHoARJZYNwjmdZO4Zun0p41zUMyq0pBA+6BnPtQbUTXchmu413kfL0IpG04KHWJ5POU5D+tAGLq/ijVtLs0MEQInOMyDIT61zOsy3XiG7S3u9kTld29F4PHau4PlziaC7wX29HGeakhsFs4Y5BEJJCAAw5FAGT4K0O10bVYZbkRzAL1967DWVScZEKglvlbH3QKqJYLNGkso8pm6gCoJRdQ3McccjSRHOQepoAijgF4/mttDoMEkfrTmD27sbSUt3Yke3ardkHivUZIWCbcujVJcKJkMyRmMhsYI6igCnb3Ub6cFR2LFiWDZyKliS2ZgQmMLl+epq+0USyxqbdYw681WvLe3g3ymXy4XXkemKAKGo39vp1vNc3CLFBjh818x/E7xlNqt7LGjn7OCQi5xx9K6P4teMCzS6faTu0KEj73BrxOaVpnLOSSfWgBjMWYk9TWxprPdaLfWY52ATqPp1/SsgIWDHB2jqa1/Cl0LTWomcBo3BR1PcEYoAxaWtzxV4evNCugZ4GS1n+eBz0ZTyOawqACiiigAopQMnA61uWHhq7ukRnKw7xlVYEkj1oAwwCTgc1r+HtLS81OOO+3xW/VuMEj0rudD0Oy0qJJIVS6nYYlaUYK+u30qLxLPaSqJLKDyggIPPWgC1NLY6Rpki6cIwOThf615nqFw11dPLJwzVLLeyOrAsy5PQGqknQetAEdWrW6FujgQRO7DG5xnH0ptnZzXspjtk3uFLYyBwBk9agxQAE5OfWkoooAKWkpaAOt8C6i6ztZNIQr8r/hXbLC7bsEfNx715NpdwLS/hnJwEYE+4r1zTbyK8gW4g5j67V60ActrMfk3QZmBB4OR3qBr2R1NpMzNGRha9K8O+GrPxH4607THQrDdctk85AycV7d4i+BPhzUtKEenqbLUI1+SYElWP+0PSgD4Wu4zFcSIRjBqGvTfiR4F1HQ72eHUbYw3MI6g5Dj1HqK8zIwaAEooooAKKKKACiiigAooooAKKKKAHxJ5kir6nFfb/wCyr4Qi0bwUdblQG81IkIx6rCpwB+JBP5V8Z+HbX7VfxoBlnYIv1JwK/Srw9p8elaBp2nxKES2t44QAMdFAoAuQmR5pSwAiGAuD19TXyJ8etXe78b6ggw0SybFJ9FGK+q/EuopoXhy8uywUxRnZnux6frXwv4pvbjUdVmluyzSFyd+eDQBkyBQAwAKn35qbTbOW5uoYoN7F22gL71VYIjDJx6HNevfCHwqQ39qTsmHBEWf50Adt4D0KLQNJjgVVaRifMJ5JzWve2ognO3f5bJ98dFNTLGqO7NKA6/LhTTL2Cd3hAIRScYJzuFAFO3WWSU+XKjRjgsw6065iV7ZpPLICE/MvBNWLglEVl3KqHHkoMD61FFcrM7CRXDyD5So4B96AIYxmyUpIxZfvIRyadBHFLGJGd0lPBQHAAFSwwGLUBJPGWkLYXB61oTWu0zEx7oCMyAcNQBm2dy2nzSlfkQ9Fxnmrs1vNPAJyqIZBnDD9arWCGba9kvmqgOVk4NaGn6rG0U1jOmJAM4POKAL9tCk9k9s/yjoSB3qpPpLvYst2cFDlSDwRVye8t47eOO0JaT+53NN1G4km0vmFwQM4xyKAMKaG0uokDMUaM59yatWEbi3YgfvOisT1rPNs+ogKuAQvykHrWlp9k+nRKbpxNGvAC/w0AVJ9Nlui+5WRM5Dn1qe5N2kMEYdlAxvkAq5fuJoYTFIfKEgJHTAqpdagZYSlsCSzFQSODQBaYW82wEhnY43etWFMAidVkz5fVRWLdXkcECb4lVouSF9a801H4nmBpoDayQMsh+ZejD3oA9ntLiOa1RwxCcnHXBqaSJ4Atxs3soznvivFdL+M+mwLKk1q+NoACnv3r1Pwd4mj8T2VxdaTb3DxQr+8LoQEOM4z0NAGpJG9zEJfMK5Tk4xUdtuRgkZLBT9xh1pbTUIXiLmaIO3ylA4P4027v7aKJMzpFLnGGOMigCW7ucIGlhw4PUnivIfjD47itdPlsbLBlI2sf7taXjX4hf2XHc2yeW6ONsbg5ANfMviTWpdQvJzKdzFsk5oAzNRvZbydnkYnPNR2kRuLmKIAncQMCoevOK6HwHt/4SexZoxIFkB2kZH5UAZ2qDyp2tkHlxp2xgk+9UoiVcMucqc5Fd38RfDdxB42msooyrSlWUHsG6fzr0vRvhFbxaJvuHJk2BmAH8X+FAHJyvP4/wDDmmaZEwSa34BkPoK5TxF8P9U0aO2kKNIkrFSQOhFe2ab4PttLSKSGJmCdXX1+ldoulWmq6a9rfCWLA+SU9j2oA+XZfAOoKcpLHIgQOSAQR+FdLpXhjTLCJRf20crbATv5J+lej3nhxLGKVp7xnI4BQfeFcX4h/wBDAMTGWNfuueoPpQBiS6Lp63TXNtHHFGOdoHGBU6ahuDgLHEm3C98VmSzXNzKZJ5Ait27VCqlpG8oZA49qAL007kFI5Nu49O1U7qWOOF3lcBU4KnuadcTxCMhogGHQ5rlNbvftEu1V2qOvuaAKl9cJLcFoV2r2qqxLHJpKKAFBIOQSD7UVr+FzpK6gza6k0lsI22pEcFnx8uT6ZqO90ie1gM8pRUPKjPJFAGYBmgg0A4II61dkukksRGIwJQ2S3qKAKNFaehaLea3fR2lhEZJXOOOle6al8JrSz8AhxbPcanEvmSMp6DHIoA+eK3/CWsPpmoxK7H7O7AMOw96oTWatNKkBwyH7pqiylGIYEEUAfT3wr1W0j8c6ZcybcCXarntuGOPzr6uPBB/Cvzc8J6zewXcflyMDGQQwOCMV+gfgDX4fEvhOw1GJss6BZQequOCDQByfx38KDX/C4voI1N3YHceOWiP3h+HWvhPxPYf2fq80S/cJyMV+ms8CXNtLBKMpKpjYexGDX50/E+yay8RX9rISWtbh4cnrgMQKAOKooooAKKKKACiiigAooooAKKKUdaAOh8LzfZbq3lbOElSQ8dgQa/SbSruHUdNtby2cPDPGsisO4IzX5qaGxBGM7S2D7V9jeGviPpvhX4f2dmLhb3UIbcCKMHGSRwDQBV/aa8SwrZ2+iQzsk6HzpAvA5GAP518zJNJlxJhweua2/Get33iHVbi91Nv30zbzhuFP90e1YJt5gA+4Mv8As9aANfwxYRatq1vaKp+d8MCOK+jbPTLbT7WO1gVfLRAFXdgivOvgxockKTanf26mNv3cR759a9Sia3kmTem2QEqQ5xigCrHBZXLywmR4JSM7gf4qhWea2jRppVkljfAcdDV2a1haciLCk8sSelJJGLVPKngVi/3GxkfSgCW6uDcxI/lIJXI+aM54pz2ZJZzcIcEbRjG361Rju3iTyTblQmCzL/DQ94i3BkEm9G+VgB1NAFpVuI3ZW2bWOVcdSfatTTLe51LzvLZllQ4Ix1+tZUUUM7rJFKFkU7mTOc+1WNK19tK1Ny+/a5yVIoAztUW50ya4UIAwH5/QUltFFcRJcThpHK43fdz7VteMbuDULWOa3h2y43b2GKwNNkluLXzSFeEArtU4KmgDutD02CApOYwWK/KcdK3dSt0+ytLHCm/bz7ivNjql9psaAeZjjb3BFXrjXbu4ijfzGD7eYweKAGuiKd627K4bA5wKkvZooyY3XLlc4B4NZzXk8sUm9MNn5d3GKit7xNpttSjzJ97fngD60Aa0E8CpFN5BVQfmHauesNcm1rxmuj6ZYs8S5Z3Iwqj61z3xC8Wjw9pUyWrF3zlATkYrW/ZOv5tctNe1K8+acTKgPQBSM4FAHr9t4R02PDyxb5DyfTNYvjX4faJq2i3QaziWVUZkYLjBxmu/wc+1ec/HbxVc+FPAt1LYQmW7u820eBwm4YJ/KgD4L1hBHrU6QHARyAPxr1fwx8ZPEXhvwFceHbDTIC0qsqXZU703DBOBwT6ZrmfBnhG6vtVSS/s59jtndt46+te86L4N0+0lmzDE6MAQXAO2gD5g0/V/EFtdbrS5uRNuz948Gr2pa94ivnL6jdTlhycmvpey+HuhJNc3TIpLDIjB71m+JfAunyWEknkLFJjAbbwaAPla8urmRsyTyP8AUmq0SiSQBjjPU12ninQIrG8niBGVOM471xcg8t2HXBoA2ryztbXSQeWmbnd6VrfCVbYeLYp7xtsEC+a3vjtXIyzyTKqsxKqMAV6Z+zv4dHiPxs8E8Re1ht2ll9MDoD+NAHq3ivSX13xRYeILVI9pjTEbdTt6V7To2nvq1qQsYiLIoJHSvIbrxDp48XyaXYtEgtiI1y3Ax1FdXq3xk0zwGLS21OwmkSUE7oSOB+NAHff8Ie0SlCyyQkcgDBzXPavYi2CwbHG1gRu/iNdV4F+InhzxvaCXQ79XkA+eCT5ZF/D/AAqx430o6hpxktXCXUfKn1oA8k1HTRd20/nQeSG6AHpivOr7R7OTzvLlyc7Wic8g+1eqatBM1hi4UkZ5bOK5bUdCiuZTJBAqucBv8aAPHtZ0mS3utjxFYfU96p31kLYFllAwe1er6hBbWsDi4tWkCjGW6ZHpXjniq6luJpniiaONc4A6CgDFudTSS7KP/qx1PvWJfNE85aHO0/pUEmSxPevYv2fvhAfiLNe3upzzWmlWmFV0XJlkPYZ7AdaAPJrTT5rk4Vdo9TXd+Ffg74p8U2E15o8EMsUZ2/NIF3H0FV/ixpz+F/GOoaNAxMdm/lh8YyMZzXS/s/fE6+8JeKYbC5czaTesEkjJ+43ZhQB59r3hifQYXg1ISQ6vHLse1K8qvrmsS6uLmULHcu52DADdq9k/af1aK5+JUd5ZBAWtk3le5Hr+GK8hjc3l0XnI9SaAKKgswA6muu8P+ELzULmHyYmmyeVUZx9awI1i+0gwKxCnJJr69/Z60S1bwx/aLgPJM3XHTFAHn3gn4fa1oeovfJbqiIMhW716/ZahFcWrQ3cYj8xdjgng1315DF5LR7V2kfrXgPjbxStjq1zZquWjbovGDQBwXxO+HC6DqEmqaRJus3bJXPKZ9q8gvlaSchhhh36Zr2LWvEd5rCmO5YmMfwVwus2McriVQq46gdaAMfQ3jtwwdwGNfRf7NfjFdJ1yXRryUCyv8GNmbhZB0/McV803aKZQYcgdDmur8OSzwpH5EmHUhkY9QRQB+h0k0cIDSMFUnqa/Pn4zMLvx94kuIyGikvZChB4IzXuNr8U7m/8AAM9jqjst9ENizKcE+hr5h16aZr653sWWRy27PWgDGpKKKACiiigAooooAKKKKAClpKUdaAL9nOYYuAeT+dem6WLuWwgeSSPbtBAIwT7V5jZqz3MMKfNlxXtaBLbSLYTwruBA5GOMUAcffTI08oZdgbj6GobOBzeRRCRSrsB9Ku6tJHPczGFUQjt2rS+Hmmyal4ntEdcoh3sMZGBQB9A+HdPj0vQbS3VsgIAeOQeuasymBnaO4kSUnBVtuDmrESi4iAQEFRgDPBxUTbEH74oGYYKsvQ0AV54kKSEMWK8be5NRW15KLZonDPznkcKKuxvCku9sLAw2vnsfao3sRsZ4pQ6ucMM84oAikmYItxABgEEoBwfrUsV08s21I4ImY9dvGKDeG3tiyrhF+Q7h1pibJWRdpUNxuAxk+lACXwKXQNh5UUmdrcdc96jvHfH71RMYxy+O9Tm1g8ry33kqTmT3+tQyRf8AEvaOGUxuh35JyW+tAEtsxe2VJJcxMcbCOgqKMiy1AxQCN4VPKY5PrVm0mK28bTxh3Zuo5wKuSm1lfKpnHQkUAUpNRhN8PNjMUe0hQ/8AKq/yPcMzKUT+Jh29Kn8SRF7GVbKykvJ0G4Io+Yn61y+g6H4zutTij1K0NtYSD96rnBx6fWgDX1TWbbT4ZDc3cUwHAGeled6vrVzrLLb6c0s5c8JGCzH2rttT+CtxreueZDfva6cT84Iyx9cV654M8D6J4QthHplqvnEDfO4y7H60AeJ+G/g5q3iW0ifX2NjaEHdHJlpT6fSvcPAXg3S/BOjjT9Hh2Rk7pGPV29TXSgikdwi7nIUDuTQA7cK5rxxpthrGmC11GITRht6qeBke9S6vr0NshEH71uny1xU+o6rqM7GbasSDPHegDOuNCl06KKW1mQWyZOz2rRtLRbiPzgyqMZPpToFjms5CyNuJ6Oen0qvFGbW9IO5Y2GEwcqaALzQIATHGnlHG51OaS6ge4s22Khi4wx7GiwSFJJkZ+X/hzxTpoxFAQd3l9cdjQB8//GHSIxHLe4jG4lT2JNfP0/8ArSB619B/HO/8mMQ+QFH3lbPBr55dizk9yaAOh0TSWv8ATppWAWJOC9dZ8JfFI8IXuvPaP881jJEjHj5uxrmNMuY0057KKUKzjJJPesNA8V0yBx1xkHrQA5tSuxdvP5riVmLFs8k5p+raxfasYzf3DzFBhdxzgUwRXN9MEjj3Y6YFO1TTLmwWN512q44oAn8O67f6JeJPp1xJBKpyGRsGvsX4DfEibxzZNY6q4N7bqN3ODIPWviRfvDmut8DeKrvwd4htdW0xwXiPzRt0cdwaAPuXxXoiIpeMHyT8xB6VyL6fEyEtvwfulT0Nafw/+Itv4703dNCsEgHzRk8Zq5PZx27yFZEVT2JzzQBxOr6dFJvjmImfZ8oA+6a8x17wqbhZoY1MXG75uM16zqFyJNRMEbRxyR/eI/irN8XRfZNDkudUu4oVCkoxPX0FAHyd4h0qXSrtkfpn1r1TwB8f9W8GeEYtDstJsZBEWK3DZDc+oHBry/xXffbtUd0ffHngjvWPsbcBjmgDZ8WeILzxNq9zqeoyGS7uXMkjeprc8AeE73VZZb5UdILYby+KwvCmiXGveILHTLZC8s8gTA7epr7W1bwtbeFPhodH0pYxdGLCuw+ZietAHxT4suLi812drmRpHB2gk5qh5awAgk7iO3auyvPDEP8Abd2lzeJC6IZMyHGSOw965Jl/fuCcgHGR3oAs6fC0isU5P86+rf2ctdt4/CL2Erqk8EpwGPUGvmTRbFrqcJAzfTFdfYC90S4R4mkRnGMZxQB9k3F0n2N5QFbI7Gvlj4pXEl54iuGEQTsdvU1oWnjPW4rUWsM0kgwct3HtVW3sru9Y310wlZgcL1JNAHBLczLhXZk52+9WAhNtJ5QyWH3a6C60C7uDJPJbNGw6EjHNYYnezd41Q7xwS3SgDm5NMmn3MI8H6VpaNaS28iK7BMng9av/AMYefPzDIC0+EwiQDb82eCe31oAmnh2sW8whXG085/SuO1u2RYnIOTnivSLDQ7/X7w2VlGpLLuyvauS8X6JdaPdfZtSt5IJ1bGHGNw9RQBwctvJGgZlIBqGu11vTf+JN5gABChunNcVQAUUUUAFFFFABRRRQAVZsIDcXSRjuetVq6rwHAkt5O7gEItADbLTHtdbRcg4+bivXlvoLXQo475IrgkfKGGcVy+m6M1/r1vLbI5J4wB2r1nxL4Xu7P4ejW0sQ7RYEileducbsUAeIXsaidmBUAkkD2r0b4Gqy6zcTMQY1Tbn0zXm19dGR5C0QUr0AHSvYPgWluNOupZITvcjD9qAPSLgBGyN6Nn5SOFpAx84yyJvA5DEcE1MLa7lRlXa6nlC/p6VEyOm+J5NjLyoxxQBVjmlmjPmJEEkY/I3rT7JUAngB8sMPlYdM1Fc2UUxMkUsizhc7uxP0qSyLiUeejP6sBwaALHlSCIWhmjdiPmwM4qlLNeWriFA5jTBDbetabRKJ1mjkCNL0IXvWtbagLG333KJN23Y6UAZ8bRvAHnSR43GeR1ql51mbU7spluhHUVtapfi6tlitYlWZhlD2xWZ9mlnCQ3SoxUfKQB1oAq6RBDqt59m0t5tufmbb8ox2r0TSfCdnaqDJukbqQx4zWR4bEWlQl5mVSeCB3rYuPE8EEbNsLkd16UAa4sreFg0caqw7gU5kWRcvggc81ylz4tWMZmXaG+4B1NVJdbvmdGiACnquck0AdyjKo+8MCmzXkEMZkmkVIx1JNcRdatemSS32hSR1TsKw7u9vZG8meEywFfnYHtQB203i+yXUIrZEkdJOBKB8uazdau4dSvkSS8kSKFsmFDgN9fWuZgh/s3ZLaMJrYjHlN2NSTWztL9oZVTcclV5oAfdMst3ILV8AcqOxqhd3F6lr52nkFcfvPMHv2rQiQ7jEoSAdmPrUwWSzI5SXevUnIoArf2pAypHKsjbwMsFxVd9QYXjR2sMlwqEAJGN2M9zVvz2vjHb2CJJfSKRtzwB6+1dt4Z0OHRNPESIpnkO+WTqWagDnH029tLQXDxBjIMkgcpWVqes29vaOk9zGvlIcoeua9MuriGC0lkuWVIo1JZm6AV8N/F3xvDqPjLVRpj4tc+XGyn72O9AGJ8WNdi1XVG8mRmUccmvOhnPFWxFcX9wwRTI/XikhtmW+WGVTndgigDt/Afw41HxLZG/V1htQcBmPJ962b34UzWs2TeQlCcK4PU16/wCB7KC28P2ltYTbLh4laVTyFBreuNDtfLk+0BS2OHX+H3oA+e7vS9T8HlRcWKOCMo4GQ1cN4k1WbUrgCdNm08LjGK+nPFqWy6GLsp9qNsAVXruPvXg/jHRLu9DaoLZYXcljEgxgfSgDjV0y+ZowLSfMmCnyH5vpVrVtA1bSH26lY3NuQAfnQiut8CfEW60TWbKXVx9strUbEVwCUX2+lfXPhq/8K/FTwtNHFCJkI2SB0wytigD5i/Z518QeLrXSr6fZaXTbOT/EelfR/wAVvh5fS6DPf+F5521CFd4gLnD49B6149rP7P2qWmvtLoN2qBH3xFztYY5r2jwX4t8QaBYQWXjeDeF+RbtDnIA6tQB8mXnjfxJpl4wvfNiuUO1vMTDcdjmue8Q+LdX8QPm/undey54H4V9k+LdN+HnxAlZpJ7Ce5XkskgR/x9azLH4H/DkxrKz8j5mBuhjFAHyJpmmxTJmTJJGQKg1SyeBt6oQP5V9H/FVPAWiQRWfh8WrXUfyny2zge5rymS50/VrSeOMRqc8E+npQBvfsrW8TePZbuYqPs8JZdw7nivTfix8U7O38ZrbQHz7a1TbKvYv7GuM/ZmisLPxveWVwVJuISI2J4OO1dL8RvgVLJq97qFjdoLSdjL85+4fSgDi/BGnaX8S/H8dvcRG3ilLMVRsHitj49fCTTfA+nWup6K0jQzSeVIjnJU44NeTaVqt14G8YJcWNwRNay/eHQ4NejfEX4uD4gWdhZXFqII4zucq3LN60Acf4Q0idkExlKR7hk9xXoF/pKNbpLEr3EiDaX7Cq/hKexW38u3iRUK4kdzyaTUrtY4ZHguHRQfudmHtQBjypIk5jhY+Yxwe2K6nQLhtIvrUamhZGcAuORiuFe4mLtJHuPsfSu38LarY6qiafqYk8wcoewFAHqHxCudHHh5DA8KySp8hBGM188X0ZeZwcqWyeeleo6r4atk0yWL7ZIYlO4KMnAPpXOSaG881vb2VoXCnBZj+tAHCKZIXG9Syr61ZgaGZjldiqcnFdv4z8LSWOjreGPyyByB615jbXCpKSepOGoA+s/gL4YtIdIk1fG9pjtQsOgHWtL44/D+18XeGWuYov+JpYAyxMo5kUdUP8xVr4C3CXPw3sWTGA7rx7GvQyM8Ee1AHwl4gsfL0t0ZQqGMjB6ivHHGGI9DX0H8ZbuGDXtXsURY2gldD+Br58fljj1oAbRRRQAUUUUAFFFFABXYeAIwZpiZCjdveuPrrvAriJ5GZTjPUUAfUv7OujLqH9o3V2ivFCVRcjnJ5r3PUtNt7/AEe506SNTbzRNEVxxgjFeW/s0vE/hbU2jLF/teGLf7oxXsFAH59+IIJLPV7uExMphkZD+BIr2H4OgweFwfJ3LJISrr1X61xnxmha3+ImuRApsNwzIF7Z7Gu5+GUCDwvCrrIr5J3KehoA70l3YyeY2DwDnGKrrcs7g3SZVDjPfHrRbxeai7nKSqOQx6025hjiZWaVsE8kfyoAsziCJY5Iowwxn5j2p4uY54Q8CybI8OQo/Ss65mldYovmkXcDkDGAKuGa5LeXb+Qu5t3y0AK6zyRrdWwCRv1R+oNPto2aNgsZmJ5dC3H4VEDqcchNyYVhOcFeabFFLPC9tIxjZRlZQcEigC7bNGVMscLRuOzdPwprMmPtEQbcwIyelVg00Nuiwkzxn5QY+amEtx9lZGtz5YHbigAM/noftEMiOq/Ky9DVq0QXUCNC7iQDcysKRLmCdI9zqmTgKTj86NSklg/f204+TgrGuc0AQ6jZzTAv8hK8BWHINVHtZ3mjaOR42XGSvNX7C5nukDSxlJCckv3FWobdpmlCloSTy2ev0oAq29syF3eVkUn5ju5NaVuHmt0ERjKg/mKoXsCugGCwXqTxuqTSzOYmhhh2Rr0waAJHtPMc7FUOhzgdDToH32zx3UBRyTgqaVGlhG4qvmZ9aZbSST3rearbOxHSgCuLWKOyljvWcZ+ZM9a5Px54wtvBWmxSXIR3cfu1J61rfEvxVaeGNLku7x4zIqkRrnJY+lfG/jTxTfeK9Ylvb5zhjhIx0UdgKAPsz9nKf+2/D1/4iuE/f3Vy0cfP3EHYfjXrRDDcc544FeT/ALPniXRh8KNLt7dTC1ohSdQvJfOS3vnNdRrGv6jexiPQbYur9ZZAVCD/ABoA4L9pnx7b6H4Rm0S1nP8Aa18ACE/5Zp3J+vSvitstNlzuLHnmvrj9oPRdF0zwBdXt6Ym1qeRRG0hzIx749sV85eAvCdzr96JZFMdlGcvKw4/CgB2rvbaYlnZ6LA73JhDTynkljzgfSp9D0J7Vhq2uK0cOfkJH3jXs+meFdIO+2SGEyquRMzAEim/CrwfbfEDxrdx3TPN4Z0YjdGW+WaQ5wv04yaAHeAtO8Wa5/pfh7SXW2Me1Lic+XG47cnr+Fa9/8O/ibGWunktZD1McM+cj6V9L28MdvBHDBGscMahURBgKB0AFSUAfIFnqtzc3c2nawPsV9CpDIVxkgelXtGgj1rRsKE3ncjM3Vh6ivQv2mPBxuvDh8VaOqxappnzTFRjzYTwc+pHX6ZryPwTqNrNYw3N0sn7oFpGVscUAeO/EDRP7D8RTW6sWjPzKcetfQH7KPi/SNK8L6ra6nNHbzQS+aGYgbkIrwX4hazBr/ie8uIWZbZPkhB54Fc7Z3U9urrAzAOMHHegD2j4wfGbU9X8QPH4fupLWyhOEZDgt71zVv8WvFi6YIL24+1WpOMyrk/nXnbxzSHIic/gank1CZtLWxZQI1fd05zQBHdX00l5LPG7Rl2LYViMUq6pfrnF3PzwfnNUjQODQA95ZHbLuxPuadDcSwnMbFa1LqbS59MtgkbxXqZErDkOO30rKJXLccHpQBsaBrE1hqEM8M7wSI25XU4INe7zfE7XdX0IWrXaA+XtD+px1NfNldFoGseW0cNwT5Y4yDQBJqunXBvZbi5y7MScj1qTQ7YrIJrhRtB4HrW5e3cTOrIN8RHGaqWkyyXAXblPT0oA6mC8tljCpHknuGwAKiurhlQMRvC9F6iq0ceJf9XuBGB6VMm60jyybue/SgCt9rDEeYQH9AcYotbj94DFOISveqrxK877ny7dVAqH7M3mYZCUBx9aAPePA9/Fq+nJAXSS8hXBZj94VuWlg1rMry258wNg46AeteDaLeXelXtvdW0rRbD90HjFehal45102a3I8p7bIVio5/GgDR+MmrFNGitYzwx55rwllI3cA5711/iXVW125M064TbhMHoa5sx+TgbGZ/wC92xQB9Q/srakLnwZfWTMN9vc7gvorKP6g17XXx/8AAjxj/wAIvrzLdYFndYjck4+hr6R8R+L7OLwpq17ZTB5IrZyu09G2nH60AfFXxM1uLUvFPiG6iR3WW9mKtnORuOK8xPJNbTTsxkj8wszFmbPr61it1NACUUUUAFFFFABRRRQAV1HhGbyJEG0sHbkVzHeul0OQw2MUyrjbJjdQB9e/syakkllq+n+SYmVkmXP8Qxg/yFe418qfBfxAmkeIba/1G4WC1kXyix4UhvX8cV9VAhgCCCD0NAHxj8dLJJPiPqskEm9jNhscYOOleg/Cm0ZvCcIlfJLEZz9z61578aZEfx/rLQqV3XBP+8e5rufhLeMfC6wJFzvJfPp60AdvFEiyOszq5H3afJaBE3txu9OcU9Fjw6mPaT02nJNZiQMZpPs7SMAOQx/OgC5A8DFC+5GclSCe1TBLSOcvbJ823axByKpeUbhYnjTAYlQDxx3qeyljtbhImt3+dtgUjKmgBIIrtroq5VoAuVxzuqxqGmySQQzbPLKHks2MiuqinsbGFkaNFbH3a5vW737WgWNdgxnGeKAM+OZo7fyoJEGxsEA96dGskxaNbhmbqdvSq9vCRvVolLuM7Rxmn6Z5sUDrDEY5lzlX9KAJ5ljkDL5au69vep9OtI0jlM6jc43YVsVWtkuPPUtFHGSTu2nrTLmREbY8Z3sSN2fuigDVsraN0BQSAb8HJzUWoXTxXMcCbxGz7Q2O9dL4ZskuNJLpJvyeuO9Z+tH7PKqbo8huAeoNAFG6ee3iBuvmUgAgDtU9uIo4mlhd/cDpilCvPC5dA757N0FOtppRC0ZiVEyfxoAkkhicKVYsG/hNcl8RfHel+DNI3XDCS452Rr1Y1X8eeObPwhaO92QbraTGoPX0r5D8beKL7xVrEt7fSFtx+VewFADPF/ie/wDE+rzXl7IxV2JWPcSFHoK7/wCCvh/wddQXOp+M70IIW/d254DD1Pr9K8ps4TLKo7E4Jq3c7kHkQO5UdT60AfXGmfGL4d6HAbXSLVoYIhgKkWA1YGrftF2wvidKsCtiOCZOGavlpw3Ric03cxGzPFAHoHjzxjqXxJ8WW4n4ieQRwRL0QE/zr3fRLeLQtHg01rdRbW6gHC4ye5Pua+aPAlwLTxdpMzsgCTqct0HPevqvWbm2S0la9T94P3hKNkY65oA8/wDi9rNnY6IJoJES7mBRVj4IHvXpX7G6Qj4Z3kqFTPJfuZTnnhVxmvlnxrrU3iXX7qcJI9rGSsQUdAOlek/steP7Twd4gutK1uUwWGpbQsjfdjkHQn2OcZoA+1qKbG6yIrxsGRhkMpyCPUU6gDmfid5X/CvPEYuNvlmxlU7unKkD9a+MrK6Gj+B7mSZcTeWVjI9TXs37T3xKSKCPwfoU0U1zcOBelWzsGchPqe9eCfEyCey0jT1klQGZQzRxnp9aAOQ8IeHNR8XeI7TSNJi827uXx7KO7H2A5r7c+HHwJ8K+ErWGS8tV1XUwAXmuRuQN/sr0x9a8Z/Yp0kT+Ktb1N0z9mtliRiOjMf8AAGvsGgDLHh7RQABpGngDoBbIP6Viat8NfBurI633hzTWLdWWEI35jFdM93HHJtkdRU6SK6Bgcg0AeLax+zb4FvYn+xw3llMSSGjmLAfga8w8R/sr6lCkkmh6xb3GPuxyqUJ/HpX1t5ybtu4bvSpKAPzw8U/B3xl4ckYXelSzIv8Ay0gG9fzFcFd2lxZymO5ieNx1DDFfqU6K4IdQwPYiuN8W/DPwv4ngkXUNLg81v+WqLtYGgD84QcEHFTOMBZYwdvf2Ne+/Ff8AZ31XQ0uNS8OSLe2KfMYcYkUfTvXgT+bbmWCZSrA4Kt2NAG5YXRuLBlLKGQY561qaXazlg28BG6GuV0twsxBBO4cV3egKq2m6ViR/dNAG1pUM0E4kz5yR84PQVemtUu70SXkg+zt/BH2qjbylxKscojUjlfWmzXPlbWQDgcc0AR3mlIlwWik3Rg498VWe38rDxyM4BxhqvyS3M7q8aIR3A7UXJCJ+8Klj0C0AUySMBlz71raRJJfQzW8auNy/dxwMVkIJixAmRVPUn1rU8MXradd+cuJCpySO/wCFAFCW2uLaQGSPDA4FI6t5uJMBWX1r0LxrqOl6vosVxYRrFdD75xgj2rzeRA6gNne3egB1j+/Z8/KE+6e2a3P+Ei1C10a8j+0ApMnltGeRj1rFs7UwK6Ak5PU027Vfs0wIbLDpjigDhNOtml1GYkBtoYnFY8o2yMPQ11PhpVlvL0BtpCnBrmbxdtzKM5wxoAipKKKACiiigAooooAK6zw5YSXmjTlMkBs4rlK774fXXk2NyrSlUY8jrmgDo7a3U2MQaWQSIuAuODXv3w8+LEE3gtrLUpwNXtIjEpJ++AMKa8GikLKsiksEBABFYRmMd0Z0jYc80AbPi+a5ur9p7qRpJmYkt616V8E5N+l3KHIKn7p6muH8QaeG0yzvI92HTdz7dq3fgvqNwmrXNuiLIki5wRyuO4oA9gS+R7rJsZQy9GPQ+9PFzn94m1d5O7HXApgurh0O5VjT7opTav5cPKnuSD2oAbaywz7mtblfNB4jYcgewpul3Upv2+2TgR5JVQvT3q+gtowJ2hUMOGIGDinR3Gn7g8A3SDhSR3oAr6j5l1IfJZiv6mow7xwRx21vvbPzbjVwqZLvzWcLs6qpqleh5Lk+XJJDgZUj+I0AWzLLLDHM1uyMGAKqOQKiuyk5U7Ji3I3L2rqPDjwxWYjv5FaRgCCe9Zmqwr/aJkjcLFnI20AY6CJrmAyyEKo4BOCSKma1invtpYNFkHdjGQabEksl20vlxyjOMHrimJLIskkbRFMfKi0Aeo6ekcenxqgAQLxgVxepx2s97IGmSXD557e1b1jfG202NJvmkC1xV+YBeMVkEcrSbsZ5oAder5RJs8EhsspOMiuY8e+PtO0GyAmRzOY+URun41D8RPEw8O6dO8TpI8h4LdRx2r5xv5NV8aa6lvbeZLJM4VV9aAMLxBql/wCKNYcqZZmdvlUksa9o+GP7N9/q8VvqHie4NlaOA3kBf3jD+leu/B34J6X4Vt4NQ1iJLrVSAwDcrGf8a9oAwAB0FAHmmj/BHwLphBTSFnOMfvmLVtL8MfBioyL4dsAp6/u67GigDybxT8CPB2sQSm0sRY3BXCtCeM9sivkf4tfDfUvh/qix3q77aXJimX7rD0+tfojXk37T2gwax8JtVuHj3T6eBcxt3GCAf0NAHwz4ft5L3WrOGIYd5VAI+te0fGLUbjRNMt7C2l3NdQhZTnLbRXmHgaNbWeXU5sBIFJXPc13/AIG8E+IPiXqbSqjC2kPzXE2dkS/57UAWfht4j0HT7WGzkihCAZkMkYYuxHOTWZ8U9OtNQdL/AEHS54VU/vGjibZz9OlfUfw6+C/hbwbBva1TU9RY5a5ukDYP+yp4A/WvSkhiSPYkaKn90KAPyoA+DfDHxl8YeEbOGytbx3t4+BHcLuAHoM9K2dZ/aA8TavpE1tLdfZjIuC1uuw/mOa+u/EHgjwz4hRl1nQ7C6LDBdoQH/wC+hz+teM+KP2ZNFnkkl8O301qjnJgn+cL/ALrdfwP50AfJemSPf6/FJO7vLLKCWLckk+td78W7RItI0x1UqwJQgnniovHnw5vvhx4rtI72SOW2lIeCZe+D3HYitH40Q30WiaS13KJI5BvQ/hQB6J+xDeD7Z4nsyeTHDMB+JH9RX1eehr4p/Y01I2vxMvLIgYvLFxk+qkN/jX2tQBxXiPUhYahh4gdxByT0rQ0XXoLuGVciIIAF3H71Z3xJspJdP8+GPey8EAc4rwhPEd6Le+tWWVZIWIjbuMUAfQNrdn+0V2kZLfMWPQV1g6V8g6T8VtT0vV1l1QCWHcqnIxgZ619Z6Tf2+p6ZbXtnKstvPGHR1OQQaAEvbxbWSPeCQ5xx2q0kiuuVPFct45lmhto7iAjbFksc1l+HfEitGP3gnJb5sHpmgDvmAZSGAIPUGvmT9pr4QWTaZP4o8PW/kzxc3MEa8OM/eA7V9LW0qyoGXkHmnzwx3ELwzIrxOpVlYZBB7UAfltbMYblDnBBr0DSZAIhuO5mxip/j34J/4Q3xxdRQIVs5282LA4APas3w5PFLaxrjEnQH0oA6bydp3Oq5I4FMeW2aP5osY4JzUBjnF1iVw20dagcls8HHcUAW4pIIJgqyjaeTVa6uEBJgyfm+VjS7I9qGJQzngg1H8yZMsYwD0FAEYuGTBkUPnrxT7e4MJM1uoRh1OeKe88T7XhXDr1yKhlYbsqYwjHkUAasEvnIS7Y3csvYGpLWAXO5V2mVR0PpWPCwBbYenQ1q+HIEu72NJ28ticDFAHpHws+H0/ifUN94dtjbnMjgj5j2WvQfij8L9HtvBGqXmm25S5tYGlGz+IAZNeifD3w/B4c8MWtpCuJHHmyserMfX9BUHxWuxY/DXxLcH+CwlA+pUj+tAHwp4Qg8q3ubjZkuSvNcbqwxqE2f71eh2KrYeHw0gKyFSw465rzW5cyzu56k0ARUUUUAFFFFABRRRQAvaux+HwE9xJCQuR8w3HArjq6DwTOYdbjAPDdvWgD0u8l+z3CrINsEoxx0BrNNiYnZcB4idwc1Lrd1NdW8sEURVl5GetUIr1nsopI1bzIziRe1AHo62qXfhtU3b5Y4yVUjrWD8O7w6f4siLOYULbZH6ba9gtPCOo33h7SLzT4olMlsrbcdRjpXhvieAab4nkW5DxtFL+8UDBBB5BoA+jZI7OXDLM0vG7APeneS5tBIn7vbkqWrF8P6lFdWdvNbIVjaMNnHX2q+yXEsZYTh0J/1dAFmN3u7dPtLqzg7sLwDVlrtS6QQ267f75HP0FVbe2jlidwCAvyhQelO80lh5Gz92OR70AV7m2k/tAMl0YsrkpjrU3nXMEBkcLMu4Kqk9B61avv31syzANK6DOzqKxm09gGQySpGSCGLZoA1zqFs7K0xdZScLgdaesikyJAjOV5PfBqXRre2uLmNZMyPEMHH866G5TS7R90MiJK/XnrQBxqusNrM7THzW+VQOorX8OKyedLKfNOzcm8c5qnPao14SkTPIG3Bk6Yq1fLcF41WVBGoIKjg/jQBNJqEZuVklmEUrD7hPFc94i1S0t7a6lnCgqpIkAqwILJ0WSbcpi4+Y1454/wBbkupn0u0zhnwwB6igDk9XutS8XaotrZiS53PtAAr6Z+Dnwq0/whZxahewpNrDpnewz5YPYe9c98CfBEFm322eHLqAdx6E+gr3ccUAFFFB6GgCleX8Vq+Zm2qBkk1HYatb6gXFqxbb3IxXnfxK1W9hilit2jMgfEYzjPtXRfDqyuf7Jhur9THcn7yjpQB2Y6c151+0Ncx23wc8S+Zn97AsKgd2Z1Ar0WvD/wBqzUlXwrpGirJiW/vRIyjqUjGT+GStAHzhpWgSeItV0HwrpsAinmIM8g9Dzk/QV9zeD/Dtl4V8PWekaamILdAu49XPdjXgX7Kvh8XGqavr93GryI3kwyHqPXFfS1ABRRRQAUUUUAeE/tS+BbvX/D8WtaWGklsFPnQgZyn98e47+30r5r8T6hLrPgTToGZnksyQwYciv0HniSeGSKVQ0bqVYHuD1r4a8e+Gz4W8cappNxkW80jNASOCrcigDhvhB4kPhT4i6LqpOI0nVJf9xvlb9DX6PxuskavGwZGAZSOhBr8uNRtzaX80JyCjkV94fs3eNovFngC1tZpd2paYiwTAnllHCt+Qx+FAHqV5brcwNG/Q15f4o+HUV1qAvdPJjbJMiqPvV6vTdi88daAPkLx34dNv50d9bi3iGQDt6+9dR8AvHZ0TRLnQ9QufMjhVntQe3tn0r0v4m/DY+LJPPhv5IHA/1ZGUNeR6t4Ti02dreyES3UKgsc4yRQBr6Z401TXvC9//AGlCcrOyM0YOFXNa/wAOkivoZBaIWRTnd05rhLDU54PDtxbwxGAOxLbRkMe+a9K/Z/ERsLkvIFfzOUIxmgD0zQ55AqR7GwDgn0rfpqIij5FA+lOoA8C/a48MnUPB8WsQoGks22yH/ZPf86+U/BcgkmeHqw5XPavv34saUda+HWvWSDMj2rsg91GR/Kvzw8PO8GshAdrElcGgDv3t5sMHR9y85X0qNo8Dhyp96twS3qwsoOSfaq9xBJjdMVYHsvWgCORZIYgH6n+L+tV5I5fMyGDZ7npVqV3WA+apYdQahdzJbBlILZ+76UAIzYAiIG/HUdKb5SuoKoGx1Ge9RPuTOI25HU9qLdGKl42JbrigC5Gls42TLJESMEgdPeur+GFhBd+L9MttyurTop3d+a5qzZ5i8brtOM7iOK7L4UNawfEHRDM4ZmuVx2we1AH2SBgADoK8i/ah19NI+F9xZAj7Rq0yWiLnnbnc5/JcfjXrtfH37S/ihfE3xCj0i1k3WOhoUYjkNO2N/wCQAX8DQB5Pqupypo7RFuAMAVwpOTmun8SlI7RVjOd56elcvQAUUUUAFFFFABRRRQAVZ06c217FKpIKt2qtS0Aez2V7bXVorIA0m3JbFc9fSy6ZqAeH/j0nG1ifWovA2oJ5ShU8yVBgqe9W/Egh8pl2ujPzsP8ACfagD7W+EN0t58N9BkEqystuI2dfVSR/SuH/AGgPAUGoabN4j063zfRIFuVUffTs/wBR39vpXOfsieNFvdKv/Ct46LcWbG4th0LoT8w/A4P419FSxpNE8cqh43BVlYZBB6g0AfKHwmv7ia1lsJGXfE3yjvXpOnRqtzK7SOJe654NcDqXh+bwJ8Srq3uARpt0d9rKOMoT0PuDwf8A69ehJNi6jigA2hfmkI6mgB93HMkgSM4V8HAPINR3S/Z5IoYDyOWcdT7VJK1vJe7Zg5kQD5+gNVTlbkeRIpdznntQBotM9yUhCGByOZCORTPshhO6e4B56Z4qMrPLBIpuFL9ye1QERJDGSWdj1dugPtQBoac0tteSr9mKIRlX/vUHbN5wnQGb+AHtVWG8uY5AZnM0AGWK9FFV1lujcSPasjWhYfvCMnHcUAaE4ks7QeXMyTKv3wcgVX+eVwHnEwA3OycU+HY8jxTkgZ+Xd0NQXMkNpay+fIkNuhwdp5YetAFDXdajtY1tooQFIyzN2HrXnfhXSY/E3jSaPazxLyZOmaueL9QW61KOKyZhFJgFyeCK9S+DfhCPT7Nr6Zle4Z+CvTHagD0rQNNi0nSre0gXCxqB7k1o0UUAFQ3swt7Z5G6KM1JG+6sjxdBPd6HcWtq2yWUbM+gNAHkM2kX3iPx4jRMbjT4W8x8Hjr0r3O3jEcKIq7QowBXK/Dzwx/wjmnPGzl3kIOTya66gAr4+/aN8QHWvi1Lp9tl4tGtBESvZ2+dv5gfhX1N418Q2vhTwrqeuXxxBZQtJj+83RV/EkD8a+CtE1K/1KTxJ4kvJUae6ctOzdS0hJOKAPpX9kiUS+F9TJclhP930Fe9186/sfxT/ANm65MQ4tQ0aLkcF+Scfhj86+iqACiiigAooooAK+cv2rtGVm0nV40xJE2yRh1I7V9G14h+1Ho+p3vhywu9OBlt45dlxEBk8jKsP1H4igD448ZQlNbkkI+WUBwfXiuu+BPjuTwP40gumJNlN+6uEB6of6ima7osup6SrrEyXNuOUKkEivOvmhkI5V1OPpQB+o2l39tqlhDeWUgkt5lDIw7irVfKP7MXxeigeLwv4gmEcb8W07ngN/dP1r6uByMjketADZF3KQa8v1zwGL6/mllnZZJchSO9epHpWZqTBI94UsyHIxQB5MPhedJ02eYzs7AEt3GPpXJeHdRl8Oa6Ht5N9k8m0jHevpRQs0ADr8rDkGvJvFWiR2useR9mAhmbKtigDtLfxAbiAME2E963dKuvtduJMg9q4/T9NeVf9FbAjADKe9ddo9qbW1CHg9aALGoBTYXIf7hjYH6YNfmVqrrH4ouWjPyC5bGPTdX6YazNHb6TezTkLEkLsxbpjBr809c8iXX7hof8AVmYkY9M0Ad5aXDTQ7WcgYAzmkdCG2LIY2B79DVWEwrACpzlePrUyXDSQYlCvt/PFACmaUM0UsRZV6Fe9QTRMmJIF256gjirrzsh8wYXcMYqMyh1/eFmyenQCgCqkzNGPMyV6HFS27RDP2dyAOue9IyvHIVVVK4zj2q1ZwQSxEcxy9hQAb4TbfI5RlPI610Hw2Z5PiJoSrD5y/akOcdOetZNzaCK3VZFDHGSyj+dangzxLb+HNdtL17Tzvs+WBHWgD6q+Kfi6Lwn4ZmlSVF1C4Ux2qk/xY+9+HWviVLd45by4ldn8xiS7cliTknNXPiD8QdZ8b+KpZ7p2SL/VwwKfliX29/epPsrWmlkySApjv1oA4PxNNmSOLuvOaxKt6tcm5vXfsOBVOgAooooAKKKKACiiigApaSigDW8NXv2LU42ZyiMcEivRNaKRQxXMObjK5y3NeTAkEEda9B8Ka2bqzS1k2F07N3oAXwrr9x4U8Xab4j09CJLWUNJGDgOh4ZfoQSK+/wDw3rVl4i0Oy1bTJRLaXcYkRh2z1B9weD9K+MbjSIJ7dRLDGzOmfl7V0/wE+JS+Btabwzr0oXQryTdBOTxbyn1/2T39Dz60AfSfj/wxaeJtDeK4gElxBmWBujBh2B98Yrzrw3e217p6SK53xkp5XcEcc17UpDKGUggjII7189eMc+G/iDdIf3VlO5kDJwF3c/zJoA7F7aARyL5gimk5K55qsbKJY2KxlgBw+etSwtHMN7Mhyo/eeoph3KNiOVwflB6YoAz72ESOiQFxMnBHY06SPzUSGSUBUADdsGr80c8dxEiLHJFNgM460stpGfM+04ZSCvy9qAKsUDRLJGkoMOOO4I9DVaFrqKwHlRCMjOfTFSzfZFZYYhJGcAEDuPWpxcL9mmiyWIIVSaAKtuW2xOGLSMcbT0qtqYEcd1NcxkhRhgegFXokljzFGmSjAg/1rB8UzpaW119puijTKQwz19qAPJbzUYbnXXVZTAgfCDPGM19bfD2KJPDNmYmDkqNzDua+Gtb1K1h1RTGpCK3GetfZXwe8QWOq+GLQWcgJCKGGe+KAPQ6bJnYdpwadRQBDaq4iHmkFvapWUMMEUtFAAoAGB0oorzb45fEm1+HvhSaWKWNtZuFKWkBOSD/fI9BQB4n+2F4+W8vrXwdpc5aK3bzr/YeGk/gQ/Tr9T7Vxngn4UeKvFHhi2XS7FE09nMktxJKE3n0GTzXAeF9NvfGniqSS4lMk8rmaV3OS7E5/Mmv0L8EaMvh7wlpWlKMG2gVW/wB7q36k0AU/hn4ch8K+CtN0uCAwvHHumBxkyHlicdT2/CuooooAKxPEHivQ/D0bNrGp21sQN2xn+fH+71qv8RtQvtK8Da3f6SCb23tmkjwMkY6kD2GT+FfEDx3esX7XN/cySyyEs0kjFic0AfbGi/EDwvrUojsNXtmc4wrttzn0zXVDkcdK+BZ7J7dCICw2/wAfTJ9q+mP2YbrWrrwPdnWZ5p7eO7MdoZjkhAo3AE843Z/WgD2KqOpWZvZLVH2m3STzJFIzvwDgfmc/hV6uGf4k6RafEqfwbqbGzvmSJ7SST7lwXGdoPY54HrQB0usaHYapp89rPawESIVDeWMqexFfnf8AFLQ30HxfeWzDA3noMcg4NfpJXy1+154Bubh7fxPpkBeEDy7kIvKN2Y+x/nQB8rRyPBMskLFXU5Ug9DX1j+zt8cBdQx+HvGFwqyJhba7c4yP7rf418mL8r4bt2q1CNzg27bZOvWgD9RIpEljWSNg6MMhgcgiho1J6V8I/DT46eI/BpjtLtzqOnKceTM2So9j2r6a8JfHTwjrtmsk90bGfbl45eg/GgD1VRgYrO1rS49TiRZOChyCOtZVr4+8K3MavFrtgVbpmUCta01zSrz/j11G0l/3ZVNAEemaStlMZEc4YYYHvWqOKpz6pYW6F5722jUd2lUf1rxf4tftBaH4atLiy8NypqWsEFQy/6qI+pPc0AZv7VPxPTQtJ/wCEX0mVW1G7XNyR/wAs4/T6n+VfGvmtvLZOSc1c13VrzXdWudS1Odp7y4cvI7dSaz6AO/8ACtyl9abGwkqDG49K3I7ZnCmQLGRwrKchvrXn/hecR3pidiqOP1rvrWMoPkfJ7pmgB81rJGiEypJk4+lR3cIhaPCHaw55zU8qic4dGGBkYNV5I5UkUZ3beeuQKAIIp1jm2PyoPHrVyEhZy8YJXqMjmkmmiuAqy24G3oR1pUkKt5gwxTovpQBcVpXikZM7duSrViz3UNrDI7HJPGPStSbVvMgKRRq0knBI6isC509577ynBwOSR6UAZlmkpv4pYUwzvncR0FdD41vIrHTgqPulkXGD2q5c2SWUKqmwhRkE1554n1N9RvzuPyR/KKAMYnJJNJS0lABRRRQAUUUUAFFFFAC0lFFADh6GpLWeS2nWWMkMpzUNPHzDHcfrQB7N4a1m21TTFdpCsyLtKg4rH8XaS1xZRzRoquW4GecVwWg6rJpd4kin5CfmFen2hh12wMsdwqqMfIetAHpP7PPxr+wLD4T8aTlI48R2d7IfuDtG59PQ9unSvWPjRpNtJpEeteUsyoVSTB4Kno2a+MPGGkGzmS4iyyZ+8K9G8IfErU5vA914dupWurVotkW85aP8fSgD1Hwprto87afex+UQAYhv3bhXbLJDLFuVSETpntXzJoWprLKsLSuLmFsqe5xXu/hDXLXW9KSHc0U33ZA3WgDoIvL+0FzMXRAABjjJqe5kZB+5Ac45GOKhe2j8r/RZRwQTx1xTriOa7EaeeIivJ2j71AFBoBDdm9nZd6oRsHerfmR3W1ZIRt27uBginsDI6ArkE/eI4FTyQkyllCt2z04oAqXMuSvkKfn+UsPSvOviS0SWVxHMGLlDhwOhFekXlokVuybguPnHPNeE/FvX3V/ItziNl5x3/GgDxbWp0knYsxZgcV2Xwl8fz+GtWgR5XFqWG4BuAPWvN76QvcOST1qBGKsCOtAH6YeEfE+neIdPimsbmOUlQTg10Nfmz4X8batoMwksbyWEjj5WIyK9q8J/tI6jYqsOqxLeRj+I8NQB9eUV88zftNaNHa7ksZHmx0zgV5x4z/aU13VbeS20iGKwjfI3pktj60AfQfxc+K+k+BNIm8qaK61dhiG2Vs4Pq3oK+FvGnijVPGOvz6pq07TXMp4HZR2AHYVm6lqN1qNy817O8sjHJZjmu6+EvgK78TX/ANuZQtjbHcWYfePZR6mgD2D9l/wLM00Go3dmBDG3nPK46kfdUD68/hX1XWF4K0caJ4etbbYVlKh5AexPb8OlUPiV4wt/B+grO7A393ILayi/vyt0J/2R1P8A9egDOi+IkWpfEn/hEvD9k98bMM2q32cQ2mBwgP8AE5OBjtz6HHe1zfw+8PWvhvwxa2tqgMso8+5mI+aeVuWdj3JJropJEjGZHVR0yxxQASIsiMkihkYFWUjIIPavk/4tfCrWfCl/c6r4fT7VoO4yYX79tk/dYd1HYj8a+lfEPiSz0uxupI57ea5gQuYfMGRxnkCvMNP+I978QfBerW1lo81rLKsls8/JRARjIGOTigDxTwZ4d17xprNlptqNkDOHuJhjbAg6sff0HrX2ZpGnW+k6ZbWFlGI7eBAiKPbv9T1r5Q/Z40LxFa/EOXybueK3twwuAvKuOwbPvXtt94l8Y6T8QtPsL+wtpPD10WBuI15T0yc8HpxQB6bXknx4+FB8fW9pqeizpZ+I9PH7iU8CVQchCexB5B7Zrv8ATvFWjajrlxpFpepJqFuu54h6ex6GtygDh/hJ4puvEfhv7PrkL23iPTW+y6jBIMMJB0cezDnP1rs7q3iureSC5jWWGRSrowyGB7GvH/HnxBtPCXxDjEdkWlIWO5dBgyIRkD3I7V63pl/b6lZx3NpIHjcA+49j6GgD4m/aH+FE/hPWX1DSYWfSrgl1Kj7nP3TXiILRt3DCv078U6DZ+JNFuNN1BN0UowD3U9iK+Kvix8KLvw9fyIsRDEkxOvKyL60AeNM+4k96fDO8OdpODxwabPC8EjRyqVdTgg1GDgUATGeTJKu4H1q3banew/6q6nT/AHXIrOFPjlZM4wQe1AFubVL6Y4lvLhx6M5NVJWLvuPJNIxzSHpQA2l70UlAE9tMYHDr94dK9B0A/bbZJk3NKvcdcV5xXe+EwYbRZFm2J14PNAHQLIrSt8zIwB+U96mtWaRVZUBXOC1aOm+EtU1+9iGk2slx5vTA6fWvdvhz8FbfTYI7nxSy3Fz1+yxt+7X/eP8X8qAPLfD/w91jxJJHJplviEjLTSDCCunvPghNaWE1zf3yxGNclk5Br6Qt4IraFYreNI4kGFRBgAfSvPPij4rsbRP7MW4ieZfnnj3cgY4BoA+Y9c0S20OB545hIX4Eg71hWInEizEM+6rHjC+fUtdIgRorYNkRE1T8TanBp+nRrBKRKF4QHpQBR8da0Et1tYCVkb7wz92vPs55NTXM8l3cPLKxZ2OSTUJ9qAEooooAKKKKACiiigAooooAKKKKACiiigB+Ny5HUda2fDWvS6PcbgN8Z4INYikqcipJEGA8f3T29DQB7VZarYatpUkc0McisnUDkGuPksjpNyjRblifkHuK5DS9TuNPlDQuQM8ivRYYG1qxjuBKCSMbQe9AC2nkPNFPZFluxyxHevRdI1GS3hW/siPNjB8+Hpn3rzTTlu9KuipgOcHaxFbsNy/krLlgTyxDYz60Ae7+FPFuna3BGltKFnVcSRn7wNdTIkZCBQSvduhFfOlvqOmwzRy2ReG6Ug7kOOfevaNB1e8n0eOW52ujKMyxjr9aANOeQmVkiUmNWyc8EU42twLvfHIAhXnJ4rNvtdtIQhZlJb5TngA+tQyX0dzE863G5YxtKqcDNAEPinUTZ6RcIw824AIXaa+XvG1/PNICzMME8E819C30yTTFRIiQlSfm53fWvFvGmgRTvPJBIWcZI28rQB5NI29yT602pJ4ngneOUYdTgio6AEp2cd6SjvQAu4mjPNPjhllYCNGZjxgCuj0vwdfXDg3g+yxY3ZfgmgCn4U8P3Ov6kkFvtWMcySOcKg9Sa+1PgRbaPNpq2ukRBrbTwBJIRw8vr7+tfLselTW0Udnpshigb77Dq5969l+GHiu78D+H5bRbcusj7w5HBPSgD6duJ47eNnmcKoGcmvmP4oXl74n8cWt2SrW9hMEtoScKq5GT9TW3r/wARb28spRFEXlZdsj9AmfSuPiiuJLdXVWDA7ixOSTQB9Xaewext2XGDGvTp0rwH9pbXda0zVdPjs5JEsREWCqcb3zXb/Brxat9o0mm6pKkV1aSbYjIwHmIeR+I6Vw/7TVxbajc6VaWlyj3VuGkdUOcA9BQB5F4c+IKadq73Gp2ckjzACXcfvCvqL4d+KtC1DQIF0ZY1DnJgRQCpPqK+XZdBa7hWS/gMQKcMRipvAniOTwlrNs1vnYJAWUt95c0AfaNjY2dgsj2ltFAZm3ybFALN6muB+N3iS30nwu9us6i9uTtiAPzD3r0W1mW5tYZkIKSoHBHoRmvln413UUvxGu4XYulqAApPCkgH+tAFP4Du1n8UYFuLiRnmRuWPLE9q+tJpEghklmdUjRSzsxwFA6k18RaDfz2fim21W3YtJEwZQPSu3+KHxj1a/wBAn02CKK3guR5cjL99l7j2zQBTl8Zab408S+Ib2dFFobnFozD5tigKD+OM/jXb+C/FN3o8hD7UjJXDM3yuPevB/Blv5FnLKyjy2Yce1dfqmrJc7IxD+6AwMdeKAPqzRfEunaptRJ447gj/AFbMOfp61L4m0Cy8RaXJZahHlWHyuPvIfUGvjZ5553SSGWSOJDnBYgp9K73w/wDEDxLpzoseqG6gDKAkp3cd+TzQB5l8W/h7c+G9Unh1BMqWJgukHDL2z715Vd6Vc2/Owup/iWvsrV9cTxTazx6vZpMI1+ZMfyrzS78FWN45GnSqir96JuooA+cmRkOGUg+4pK9ovPCVrcCSHyw7RcFgMZNZM/gWxVD5qzRNjOAKAPLaSu8u/DGkQSHFxOUxwCO9VTb+HrXG+C4lkA+ZS3BNAHHAZ6U4RSE8I35V32n3+ipOn2TRBI2B8hy2TXZ6b4a8XeI9i6P4Skjg7O8Hlr/302KAPFIrOaWQIEK57txXrfwi8H3XiTUl0zS4GuJYyHmuGBEMA9WP8h1Neo+Ev2bbu+uY7vxnqK20OQTZWR3OfYv0H4A19E+GPDuleF9Ji03QrKKztI/4UHLH1Y9Sfc0AQeEfDFj4Y0xLWyTL4HmTEfNIfX2HtW7VDWdYsNGs3utSuo4IUGSWPJ+g718/fFD4zT6np11p/hZpbKNso1yeJHH+z/dz+dAHU/GD4zWvhw3Gj+Gniu9aT5ZpOsdv7f7T+3bv6V8xjUbvV7+S6vZnWeRizs5+8xPWsACeCXfKSSxJ5qpqOuNFhYSGf19KAN3xBqcenncJBJPjjHNcFd3Mt3M0kzFmJ7024nkuJC8rFmNR9PrQAp4GB+NNoooAKKKKACiiigAooooAKKKKACiiigAooooAKfG5Qn0PBHrTKKAHuu05HKnoa09B1mfSbtZIySoPKk8VmxvtBDDKnqP60SxlCOcqehHegD0+38QyamokDKVIwy96t20qLEXmXdBnHHrXlVleTWcyyQuQRXe+HtXg1FBFI6xTZ/i6E0AdG7RZSSGJY4HwT3OK91+ANxptzDcWYu90mciCQ5yPavBpIIxOAQSvqp+WrUNrLp7RXGn3TwXEbb1ZWIIIoA+utf8AAOg65Gi3VsY2RtwaJtpJ96wn+FltEZjY6rdRiT/lnIiuoP6GuR8FfG8q1rY+LLRwWAUXsPIPuy/1H5V7Zpuo2ep2y3Gn3MNzC3Ro2DCgDxrVfhj4hW5aWC4s7uNBlFUlGb1GDx+tebax4K1+HUJPM0me3hJzscfLj6jjFfXFIwDAhgCD1BoA/Or4heD9UsdQW6+yhrab7rxkEfpWbZ+Addu7H7XFa5hPQ55NfoTrHg7w/rFs1vf6VbPEzbiFXZz6/LisGD4W+GrIiSJblI4wSFaclF9Tz/WgD4k034cancDfckQxgjcT2rrLTwDoWlRrLfTSXhY/KFGBn0rX+I2oadY+O5rLw3qT3NqxClxygbuB61rxaW62Vubl5FXJ2lhwSaAKiWGmpaeZb2EdgMfIzDJP51V/spL2JHuGlaNjhWdsbvpU97E8lwkOoSyeUuWAFW0uraRLeG2tJJkU5G/gL9KAK1nDEJpIVSON0GEVu1aF9JPFDaQXLgnOdvaoLe4tbnW3F9G6lRtG1cGtScNJqMNultutwRh2H3R60ARSX0blIZArRRqPlUYJb3p3nSrbNPdA29oT91epq1qzQwtIIYhJcKvUDriqmo3QudJhinULIVJCjsaAOL1zXLJVe2R2cbt6sOGX0rJ8O6hKs9xPcmSbPQscmt+40Gz861UKzSyoS3FM0/SY7DXow6+ZEo+dWNAGtJdRanCD5zn5M4PY+lctqWlNOss6hknjPygdxXo954Ut/wCyVvNMf53YBlU/drnrmZdKv4/PVemGz3+tAH1B8KLqW8+HOgTT5802qq2fbI/pXgXxv0tB8Rb1oyzvclCV9PlAr6N8D2iWPhHSbeM7kW3VgfXPP9a8d/aA03+zvEdhrbsFt518on/poO35UAeYaNZRRX8MMCZdTiQE1z2r6Fdah4gu51K/ZoclUPrXfW1hY2VjHeedvup5BsVW5Gfb0pmsT21jemLnLL8wx1zQB5H4fu9XsdakjMWYCfuuPlrunW+jdpTAFVhkLjgVK8ce3zBDlAcBiK0bW+N3HOkyAIqnaaAMG+MNxhGVo5CuGxwDWGu+xnIj3GNeQc10F1NHIF2sWlzgnGcCqkVuJfMijIO5ucigDotH8SNLHA+4hguJGHU+1WodT0e7ndpJJbO9BxuB4Iqp4ds9PhDxTj52BVQDjn1rG8TaMumlZC/mNL8y88qKAOgvI0jkOy5S5jc8CPhgazbh5rMNJ9rAQDlH6mq1pLCkELwFy4HznuDWbrUMWqyFvOeKTpjPWgCabZcbmeOEqQfvVmxaZpsl2hmizHuAIB5NSHTfKshEZ2Y4zz2qfT4m8kQsqlh0Y96APevAi+BPCNnHcm1t1uGAPmyKHcZrsPEPxc8H6DZefd6ju44jiQsx/Cvmaysbr7bt1AsIuMknAUVQ8X2NtqrLb2ceI4+DIOd1AHrc37R41S++zeG9J+TODNcvjj6CjVvjXfQWZWWREuOwiWvDNNsEtoxb2iFCThpCMflXQz6TZWloZbi4V5D/ABHoPagDJ8Ua74g8R3xudQuJPs7HjLdqzdQubW2tNrSZx/Fnk1ma/wCI44t1vBh2HRh0FcXcXEtw5aRic9s0Aaur601yTHB8sfQHvWL1NGO/aj6UAHSkoooAKKKKACilpKACiiigAooooAKKKKACiiigAooooAKKKKACnq5AKnlT1FMooAlaFhF5ijMecZHY+hpiMUYMpIYdCKdFI0bZU8dwehqQokxHlDa5/gPT8DQB0mi+K5IYhbXg3RHjd3FdVp9+rRmWC6+0K3BQnnFeVspQ4YEH3qSC4lgbdDIyMPQ0Ae2I1rdQblcxOhyu41Z8PeJ7vSZ5BYXc0Vyf+WqNtx715LaeJLgFVuTuXuR1rorPUbK85ScKzcYPBoA9fs/jt4w0PU4or0WWsWTkD54/Lcf8CXH6g17Vo/xc0a8ghe8tru0Mi5yQGXP1/wDrV8oacwwUKrKhGFc9q0tT/tO40uL7PKf3WSsffFAH1Zd/FLwvbEqbqaST+6kRJrivGPxAj8Q2cmnWZMEMhwSWKkj3/wAK8L8F6lfv9oOoxMCRtBZcmuv+wJdgSMrRJj7+aAOfnsrGxUzQ2qPIZMbsZzVi41a71GeO3lMkVtGBt471fuLP7GIllfzVbhVHXHrSX9yfLhKInlZC5/iH1oAt3GlSi0jkLJMcH5XPINcrcLfNcxjfJFIG+RK0rgXkzyFrvzIs5THWrVlN5yrP5ubhDhgBkgUAFuUt4prpjI95gKxPQGrExvtSslLO0DowXIOM0ySNxHMAQWcmQMT1H0q5awzW7IolEhwDjP3c0AQxm9+0OwRcKojLMfve9NkMQvdsS+ZMuQeOKLuO+tZi0oDI7fLtOcUttC8WrySwSqSwGU7nNAFQGb7dAUyJRnd6AVLHp7TXsk07FecBhzk1v3UKQw2770WUE7iRn8Krz3d2bPyIbeJpJJMDac5/woAxWtb/AE6x1C5MrDA3RKG4P4VzdncWWs3dld6lwfNCzDdxjjNW/HHiN9P0d7eZTHMoKYJ+8a8WXWbpM7XIBOcUAfpZpmqaSNItpLW9tRZrGqo3mqFAAwB1ryL9pDxf4YbwStodQtLu++0o8McMgcqRnLHHQYNfFc2p3cyFXuJCpOcbjiqskrufmYn6mgDsrLxJcPr8UkU7rhgFyeK9kWU3d3BLexrIfLBJ/CvmiORo5FdThlORXpvhb4lNa2y2moQq69N/oKAO9AUyOjI3kbixI9K1YksSjfZtwgmGFyO/1rm7XxVpk6KFnh8sDG3PJzWh5thJbRyWd0nloSTGH557igBjIsDNBLb7Wzu3d8VWSKORJGEmEJ4OMEH0q8urWtzEkYcSuM7WU5b6VJa3Nve6hClxCsUedpxwCfWgCINGsFuzYWfd949RVbVZvOEtvcBWY4wepxVrWLyytb26W52kIB5S+9UYmW7gaWEg4ORnrQBW0yFVuHSIYlUcI38VJMLTzd8yNHNn5lFXAwtZEZQvnd2YcH6Uy8Vri6YCJZS45C9qALk/kXsMTLGsShQMnvUbW8IlaKIbZFAKn+8arWvlfZ/LUEMuQwJ5X2FSLeWiN9qacoUO3BPtQBkXl1qLyyR37OIcj5R6Cr8sCPbwNBlEI5ANZGv+LNPRwzziUjgqB1rh9a8Y3N0pitP3UXYjrigDuNV8Tabpdu8U4WedfubeCK851vxPeakGj3GODOQoNYckjyOWkYsx6k0KmepCj1NADSSTzkmlwB15PpS5A+7+dMoAUkmkoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAWkoooAKKKKAJhOxAEvzqOAD2+lOKQyY8pyjH+F+n51XooAklieM4Yfj2pgJByCQaVXZeh49D0p25G+8uD6rQBr6b4hvLIoA+9FPQ13Oh+PrYSKs8XlkDnnINeYCLccRkN7d6YVZThgQfegD6FsNZ06/3ywXCCSQ5JPattdTga3w53BjtwD1NfMcFzNAf3UjL9DWxaeKtTtiNk5IHPNAH0LJJuiUlPLZfmAHUdqoWcQaa4IQ+UPmZm6/gK8oj+JGoskYnVWKDGR3HvV7SviBDHcrJcRyAnO4A8c0AejafaLJPIyODu5THGPrTbZPJuxLIfKaPOZD0Yd64q18b2RR0Nw8W48EdQKmPiXS7yAiS+Ixxhu9AHeMYdRd0heHy8fK+7DAelaCCUTQqhTyU755bivLJtV0uHY1pe5IHTPeqMniIo246gcDoAaAPXJpGiR3uJQpUkjHIqtc6pp1vCjxlTcP1dj0ryuXxoi2xhlkeYHnOaxtS8XJcRBY7bLqMBielAHrtxr+lWULtLeh3kOSucge9cjq3xRjtmePTLcZUFVc+vrXk9zcy3Em6RiahwfSgDR1rWbvV7gy3chbnIGelZtKBnrT1CAfMaAGAcZpADUqyBDlQPxpYY5riTZBGzseyigCIDNIauTadfQIXltpVUdSVNVW3ZwR+FADQxU8EirEN7cxcJM4B7ZqA0enFAHRaJ4gawPzFg3dga3/+Evjyo80gZz9DXnpNBxQB6LPrWnXA3XV2ZGJzkdRV/R/GWlabIWXfIoG0oe4ryvijPFAHrFz8RrL5vJtt6kbdjjOPpWVJ4/KyNLBGUc/3TivPACegzUq20zDIjbHqRigDrb/x1eT/AOqRY37sK5y81e9u3Zpp2O45IBqv5CouZZUB/uryaYGiU8KW/wB40AM5Y9yakWDjMjrGPfr+VJ5zgEKdoPYVGeaAJXaNDiIFv9ph/SoiSTk0lFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAC9DxUizyL1O4ejc1FRQBYEsLf6yHn1Q4pTHbt9yUr7Ov9RVaigCytpI/+rKP/ALrCo3glj+9G4/Co84PFSJPKn3ZHH40AMII6gikq2uo3QABk3AdAyg0v9oOQA8Nu/wBY6AKmTRuNXjqCMADZW31AI/rR9uh37vsFv0xjnFAFDJozWj/aaj7tjaj6qT/Wlk1eZkCrBaoB02xDNAFGKKWRsRxsx/2QTWhDoWpykYtJVyM5cbRj8ajOs6hk7blkzx8gC/yqvcXt1cHM9zNIcY+ZyaANaLw8VP8Apt/Z2w7lpAcfgKtRad4chkb7XrDyKD0hiZs1y1FAHYLc+EIUYC31Cdx91jhR+VVZPEy2jg6HaLZsBjzD8zVzNFAHRHxnrshAur5rlAfuTKGFDeJEkcGfS7R8dSMgmudooA2L/WhcBVgsba3Qei7ifxNRJd2DqPtFk28dTHJgH8DWZRQBoyXNgM+TZMc/35On5UsNzpwQiexct2KS4/pWbRQBde4tNw8uzwo7NITmka8jD7orWFPY5b+dU6KALTX05OVKJ/uKBUMk0khJd2b6mo6KACiiigAooooAKKKKACiiigAopwXPUgCkPXigBKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiilAzQAlFOxSYoASiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axial image on abdominal CT demonstrates splenic injury and perihepatic fluid. Abnormal densities in and around the&nbsp;spleen&nbsp;may represent intrasplenic or perisplenic hematoma. Pools of contrast (white puddles and streaks) in the spleen suggest active extravasation and/or pseudoaneurysm formation.",
"    <div class=\"footnotes\">",
"     CT: computed tomography",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lewis J Kaplan, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38083=[""].join("\n");
var outline_f37_12_38083=null;
var title_f37_12_38084="Lidocaine and epinephrine: Pediatric drug information";
var content_f37_12_38084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine and epinephrine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?28/52/29510?source=see_link\">",
"    see \"Lidocaine and epinephrine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/23/9588?source=see_link\">",
"    see \"Lidocaine and epinephrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lignospan&reg; Forte;",
"     </li>",
"     <li>",
"      Lignospan&reg; Standard;",
"     </li>",
"     <li>",
"      Xylocaine&reg; MPF With Epinephrine;",
"     </li>",
"     <li>",
"      Xylocaine&reg; With Epinephrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xylocaine&reg; With Epinephrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Injectable",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/52/29510?source=see_link\">",
"      see \"Lidocaine and epinephrine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage varies with the anesthetic procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Use lidocaine concentrations of 0.5% or 1% (or even more dilute) to decrease possibility of toxicity; lidocaine dose (when using combination product of lidocaine and epinephrine) should not exceed 7 mg/kg/dose; do not repeat within 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection, solution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     0.5% / 1:200,000: Lidocaine hydrochloride 0.5% [5 mg/mL] and epinephrine 1:200,000 (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     1% / 1:100,000: Lidocaine hydrochloride 1% [10 mg/mL] and epinephrine 1:100,000 (20 mL, 30 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% / 1:100,000:  Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (30 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Xylocaine&reg; with Epinephrine:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.5% / 1:200,000: Lidocaine hydrochloride 0.5% [5 mg/mL] and epinephrine 1:200,000 (50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1% / 1:100,000: Lidocaine hydrochloride 1% [10 mg/mL] and epinephrine 1:100,000 (10 mL, 20 mL, 50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2% / 1:100,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (10 mL, 20 mL, 50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection, solution",
"     </b>",
"     [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     1.5% / 1:200,000: Lidocaine hydrochloride 1.5% [15 mg/mL] and epinephrine 1:200,000 (5 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% / 1:200,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:200,000 (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Xylocaine&reg;-MPF with Epinephrine:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1% / 1:200,000: Lidocaine hydrochloride 1% [10 mg/mL] and epinephrine 1:200,000 (5 mL, 10 mL, 30 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1.5% / 1:200,000: Lidocaine hydrochloride 1.5% [15 mg/mL] and epinephrine 1:200,000 (5 mL, 10 mL, 30 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2% / 1:200,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:200,000 (5 mL, 10 mL, 20 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection, solution",
"     </b>",
"     [for dental use]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% / 1:50,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:50,000 (1.7 mL, 1.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% / 1:100,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (1.7 mL, 1.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lignospan&reg; Forte: 2% / 1:50,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:50,000 (1.7 mL) [contains edetate disodium, potassium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lignospan&reg; Standard: 2% / 1:100,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (1.7 mL) [contains edetate disodium, potassium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Xylocaine&reg; Dental with Epinephrine:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2% / 1:50,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:50,000 (1.7 mL; 1.8 mL [DSC]) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2% / 1:100,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (1.7 mL; 1.8 mL [DSC]) [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local injection: Before injecting, withdraw syringe plunger to make sure that injection is not into vein or artery; do not administer I.V. or intra-arterially",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local infiltration anesthesia [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F188672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Degree of adverse effects in the central nervous system and cardiovascular system are directly related to the blood levels of lidocaine. The effects below are more likely to occur after systemic administration rather than infiltration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Myocardial effects include a decrease in contraction force as well as a decrease in electrical excitability and myocardial conduction rate resulting in bradycardia and reduction in cardiac output.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: High blood levels result in anxiety, confusion, disorientation, dizziness, restlessness, seizure, and tremor. This is followed by depression of CNS resulting in somnolence, unconsciousness and possible respiratory arrest. In some cases, symptoms of CNS stimulation may be absent and the primary CNS effects are somnolence and unconsciousness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypersensitivity reactions: Extremely rare, but may be manifest as dermatologic reactions and edema at injection site. Asthmatic syndromes have occurred. Patients may exhibit hypersensitivity to bisulfites contained in local anesthetic solution to prevent oxidation of epinephrine. In general, patients reacting to bisulfites have a history of asthma and their airways are hyper-reactive to asthmatic syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Psychogenic reactions: It is common to misinterpret psychogenic responses to local anesthetic injection as an allergic reaction. Intraoral injections are perceived by many patients as a stressful procedure in dentistry. Common symptoms to this stress are diaphoresis, generalized pallor, fainting feeling, hyperventilation, palpitation.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to epinephrine, lidocaine, amide-type local anesthetics, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use solutions in distal portions of the body (digits, nose, ears, penis); do not use large doses in patients with conduction defects (ie, heart block)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chondrolysis (necrosis and destruction of cartilage) has been reported following continuous intra-articular infusion of local anesthetics for extended periods of time (48-72 hours); patients presented as early as 2 months following the infusion with joint pain, stiffness, and loss of motion; more than 50% of patients required additional surgery, including arthroscopy or joint replacement; intra-articular administration of local anesthetics is not an FDA-approved route of administration. Some products contain sodium or potassium metabisulfite which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F188662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: EPINEPHrine (Systemic, Oral Inhalation) may enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F188631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F188643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lidocaine blocks both the initiation and conduction of nerve impulses via decreased permeability of sodium ions; epinephrine increases the duration of action of lidocaine by causing vasoconstriction (via alpha effects) which slows the vascular absorption of lidocaine",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-6 hours, dependent on dose and anesthetic procedure",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use preservative free solutions for epidural or caudal use",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12552 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38084=[""].join("\n");
var outline_f37_12_38084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188651\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188652\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053633\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053630\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188634\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188620\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053636\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053635\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188672\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053639\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053629\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053628\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188662\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188629\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188631\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188643\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053627\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053638\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053640\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12552\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12552|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/52/29510?source=related_link\">",
"      Lidocaine and epinephrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/23/9588?source=related_link\">",
"      Lidocaine and epinephrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_12_38085="Amiloride: Drug information";
var content_f37_12_38085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amiloride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/32/3589?source=see_link\">",
"    see \"Amiloride: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/58/17317?source=see_link\">",
"    see \"Amiloride: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Amiloride&reg;;",
"     </li>",
"     <li>",
"      Midamor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Potassium Sparing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension, edema (to limit potassium loss): Oral: Initial: 5-10 mg/day (up to 20 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Hypertension (JNC 7):",
"     </i>",
"     5-10 mg/day in 1-2 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F133065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/58/17317?source=see_link\">",
"      see \"Amiloride: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension (unlabeled use): Children 1-17 years: Oral: 0.4-0.625 mg/kg/day (maximum: 20 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 5 mg once daily or every other day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F133050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manufacturer&rsquo;s recommendations: Use of amiloride in patients with diabetes mellitus or S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.5 mg/dL should be done with caution and is contraindicated in patients with anuria, acute or chronic renal insufficiency, or evidence of diabetic nephropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternate recommendations (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer at 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F133022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food or meals to avoid GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Counteracts potassium loss induced by other diuretics in the treatment of hypertension or edematous conditions including CHF, hepatic cirrhosis, and hypoaldosteronism; usually used in conjunction with more potent diuretics such as thiazides or loop diuretics",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F133077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cystic fibrosis; reduction of lithium-induced polyuria; pediatric hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F133089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       AMILoride may be confused with amiodarone, amLODIPine, inamrinone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, fatigue, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (up to 10%; risk reduced in patients receiving kaliuretic diuretics), hyperchloremic metabolic acidosis, dehydration, hyponatremia, gynecomastia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, diarrhea, vomiting, abdominal pain, gas pain, appetite changes, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, arrhythmia, bladder spasms, chest pain, dyspnea, dysuria, GI bleeding, intraocular pressure increased, jaundice, orthostatic hypotension, palpitation, polyuria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F133025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amiloride or any component of the formulation; presence of elevated serum potassium levels (&gt;5.5 mEq/L); if patient is receiving other potassium-conserving agents (eg, spironolactone, triamterene) or potassium supplementation (medicine, potassium-containing salt substitutes, potassium-rich diet); anuria; acute or chronic renal insufficiency; evidence of diabetic nephropathy. Patients with evidence of renal impairment or diabetes mellitus should not receive this medicine without close, frequent monitoring of serum electrolytes and renal function.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/electrolyte loss: Excess amounts can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia:",
"     <b>",
"      [U.S. Boxed Warning]: Hyperkalemia can occur; patients at risk include those with renal impairment, diabetes, the elderly, and the severely ill. Serum potassium levels must be monitored at frequent intervals especially when dosages are changed or with any illness that may cause renal dysfunction.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cirrhosis: In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with extreme caution in patients with diabetes mellitus; monitor closely. Discontinue amiloride 3 days prior to glucose tolerance testing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabolic/respiratory acidosis: Use with caution in patients who are at risk for metabolic or respiratory acidosis (eg, cardiopulmonary disease, uncontrolled diabetes).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: AMILoride may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F133040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Hyperkalemia may result if amiloride is taken with potassium-containing foods.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4930891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F133054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F133029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food or meals to avoid GI upset. Do not use salt substitutes or low salt milk without checking with healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F133028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (AMILoride HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $128.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F133016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I &amp; O, daily weights, blood pressure, serum electrolytes, renal function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F133030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alverix (CY);",
"     </li>",
"     <li>",
"      Amiclaran (CZ);",
"     </li>",
"     <li>",
"      Amiduret Trom (DE);",
"     </li>",
"     <li>",
"      Amikal (DK);",
"     </li>",
"     <li>",
"      Amilamont (GB);",
"     </li>",
"     <li>",
"      Amilo (KP);",
"     </li>",
"     <li>",
"      Amiloberag (DE);",
"     </li>",
"     <li>",
"      Amilorid NM Pharma (SE);",
"     </li>",
"     <li>",
"      Amilozid (HN);",
"     </li>",
"     <li>",
"      Amiride (IL);",
"     </li>",
"     <li>",
"      Berkamil (IE);",
"     </li>",
"     <li>",
"      Conserve (PK);",
"     </li>",
"     <li>",
"      Edepin (TW);",
"     </li>",
"     <li>",
"      Kaluril (AU, TW);",
"     </li>",
"     <li>",
"      Midamor (AT, CH, FI, GB, IE, NL, NO, NZ, SE);",
"     </li>",
"     <li>",
"      Modamide (FR);",
"     </li>",
"     <li>",
"      Moduretic (Combinado con hidroclorotiazida) (MX);",
"     </li>",
"     <li>",
"      Nirulid (DK);",
"     </li>",
"     <li>",
"      Pandiuren (AR);",
"     </li>",
"     <li>",
"      Puritrid (FI)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F133006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks epithelial sodium channels in the late distal convoluted tubule (DCT), and collecting duct which inhibits sodium reabsorption from the lumen. This effectively reduces intracellular sodium, decreasing the function of Na+/K+ATPase, leading to potassium retention and decreased calcium, magnesium, and hydrogen excretion. As sodium uptake capacity in the DCT/collecting duct is limited, the natriuretic, diuretic, and antihypertensive effects are generally considered weak.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:~15% to 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 350-380 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 23%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: No active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 6-9 hours; End-stage renal disease: 8-144 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (equal amounts as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38085/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaffey L and Martin A, &ldquo;Malignant Hyperkalemia After Amiloride/Hydrochlorothiazide Treatment,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1981, 1(8232):1272.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleyman TR and Cragoe EJ Jr, &ldquo;The Mechanism of Action of Amiloride,&rdquo;",
"      <i>",
"       Semin Nephrol",
"      </i>",
"      , 1988, 8(3):242-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38085/abstract-text/2849182/pubmed\" id=\"2849182\" target=\"_blank\">",
"        2849182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38085/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38085/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang L, Sheldon RS, Mitchell LB, et al, &ldquo;Amiloride-Quinidine Interaction: Adverse Outcomes,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1994, 56(6 Pt 1):659-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38085/abstract-text/7995008/pubmed\" id=\"7995008\" target=\"_blank\">",
"        7995008",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8550 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38085=[""].join("\n");
var outline_f37_12_38085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708618\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133045\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133081\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133048\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133065\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133049\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133050\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682644\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133018\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133003\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133022\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133021\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133077\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133089\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133079\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133025\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133007\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298733\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133012\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133040\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133014\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4930891\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133054\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133029\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133028\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133016\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133030\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133006\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133024\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8550\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8550|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/32/3589?source=related_link\">",
"      Amiloride: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/58/17317?source=related_link\">",
"      Amiloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_12_38086="EP study tracings AVRT concealed pathway";
var content_f37_12_38086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study showing orthodromic AV reentrant tachycardia in concealed accessory pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 421px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (I, aVF, and V1) and intracardiac recording from the high right atrium (HRA), proximal (HBE3-4) and distal His bundle region (HBE1-2), proximal to distal coronary sinus (CS9-10, CS7-8, CS5-6, CS3-4, and CS1-2), and right ventricular apex (RVA3-4) in a patient with atrioventricular reentrant tachycardia (AVRT). During an orthodromic AVRT, there is retrograde atrial (A) activation which occurs after ventricular activation (V); the earliest atrial activation (arrow) is seen in the lateral mitral annulus (CS1-2) due to a concealed left lateral accessory pathway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38086=[""].join("\n");
var outline_f37_12_38086=null;
var title_f37_12_38087="Plaque sarcoidosis";
var content_f37_12_38087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52189%7EDERM%2F59868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52189%7EDERM%2F59868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plaque sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Well demarcated, red-brown, infiltrated plaques are scattered on the back and posterior arm. Hypopigmentation is present at the periphery of some lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plaque sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular sarcoidosis. Erythematous, indurated, ring-like plaques with central clearing are present on the back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38087=[""].join("\n");
var outline_f37_12_38087=null;
var title_f37_12_38088="Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information";
var content_f37_12_38088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"33\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2b: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/8/30854?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2b: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      PegIntron&reg;;",
"     </li>",
"     <li>",
"      PegIntron&trade; Redipen&reg;;",
"     </li>",
"     <li>",
"      Sylatron&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PegIntron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1029894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Biological Response Modulator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Interferon",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1029929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"      see \"Pegylated interferon (peginterferon) alfa-2b: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to differences in dosage, patients should not change brands of interferon alfa therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Chronic Hepatitis C:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer labeling: Children &ge;3 years and Adolescents: PegIntron&reg;: SubQ: 60 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly (in combination with ribavirin). Treatment duration: 48 weeks (genotype 1); 24 weeks (genotypes 2 and 3). Consider discontinuation of combination therapy in patients with HCV (genotype 1) at 12 weeks if a 2 log decrease in HCV-RNA has not been achieved or if HCV-RNA is still detectable at 24 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adolescents who reach their 18th birthday during treatment should remain on the pediatric regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternate dosing: American Association for the Study of Liver Diseases (AASLD) recommendations: Children &ge;2 years and Adolescents: PegIntron&reg;: SubQ: 60 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly (in combination with oral ribavirin) for 48 weeks (all genotypes) (Ghany, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Melanoma:",
"     </b>",
"     SubQ: 6 mcg/kg/week for 8 doses, followed by 3 mcg/kg/week for up to 5 years.",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with acetaminophen (500-1000 mg orally) 30 minutes prior to the first dose and as needed for subsequent doses thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Chronic Hepatitis C:",
"     </b>",
"     Administer dose once weekly.",
"     <b>",
"      Note:",
"     </b>",
"     Discontinue in patients with HCV (genotype 1) after 12 weeks if HCV RNA does not decrease by at least 2 log (compared to pretreatment) or if detectable HCV RNA present at 24 weeks. Discontinuation is also recommended in patients who previously failed therapy (regardless of genotype) if detectable HCV RNA present at 12 or 24 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Monotherapy: Duration of treatment is 1 year; Initial dose (based on average dose of 1 mcg/kg/week):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;45 kg: 40 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     46-56 kg: 50 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     57-72 kg: 64 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     73-88 kg: 80 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     89-106 kg: 96 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     107-136 kg: 120 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     137-160 kg: 150 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Combination therapy with ribavirin: Treatment duration is 48 weeks for genotype 1, 24 weeks for genotypes 2 and 3, or 48 weeks for patients who previously failed therapy (regardless of genotype). Initial dose (based on an average dose of 1.5 mcg/kg/week):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;40 kg: 50 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     40-50 kg: 64 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     51-60 kg: 80 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     61-75 kg: 96 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     76-85 kg: 120 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     86-105 kg: 150 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;105 kg: 1.5 mcg/kg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Association for the Study of Liver Diseases (AASLD)  recommendation: Adults with chronic HCV infection: Treatment of choice: Ribavirin plus",
"     <b>",
"      peginterferon",
"     </b>",
"     ; clinical condition and ability of patient to tolerate therapy should be evaluated to determine length and/or likely benefit of therapy. Recommended treatment duration (AASLD guidelines; Ghany, 2009): Genotypes 1,4: 48 weeks; Genotypes 2,3: 24 weeks; Coinfection with HIV: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     <b>",
"      Chronic hepatitis C:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents:",
"     <i>",
"      Combination therapy with ribavirin:",
"     </i>",
"     Serum creatinine &gt;2 mg/dL: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Monotherapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Reduce dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemodialysis: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Discontinue use if renal function declines during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Combination therapy with ribavirin:",
"     </i>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Combination therapy with ribavirin is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Decompensated liver disease or autoimmune hepatitis: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic decompensation or severe hepatic injury during treatment (Child-Pugh class B or C): Discontinue immediately",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Chronic hepatitis C:",
"      </i>",
"      Dosage adjustment for depression (severity based upon DSM-IV criteria):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild depression: Children, Adolescents, and Adults: No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule. For worsening depression, see &ldquo;Moderate depression&rdquo; below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate depression: Evaluate once weekly with an office visit at least every other week. If depression remains stable, consider psychiatric evaluation and continue with reduced dosing. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; continue reduced dosing or return to normal dose. For worsening depression or development of severe depression, discontinue therapy permanently and obtain immediate psychiatric consultation. Utilize followup psychiatric therapy as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children and Adolescents: Decrease to 40 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly, may further decrease to 20 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Monotherapy: Refer to adult weight-based dosage reduction with monotherapy for depression below",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Combination therapy: Refer to adult weight-based dosage reduction with combination therapy for depression below",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe depression: Children, Adolescent, and Adults: Discontinue peginterferon alfa-2b and ribavirin permanently. Obtain immediate psychiatric consultation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Chronic hepatitis C:",
"      </i>",
"      Dosage adjustment in hematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemoglobin decrease &ge;2 g/dL in any 4-week period in patients with pre-existing cardiac disease: Monitor and evaluate weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemoglobin &lt;10 g/dL: Decrease ribavirin dose to 12 mg/kg/day; may further reduce to 8 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     WBC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutrophils &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelets &lt;70,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Reduce peginterferon alfa-2b dose to 40 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly; may further reduce to 20 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL, WBC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutrophils &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Permanently discontinue peginterferon alfa-2b and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemoglobin decrease &gt;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose by 50%; decrease ribavirin dose by 200 mg/day. Hemoglobin &lt;12 g/dL after dose reductions: Permanently discontinue both peginterferon alfa-2b and ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemoglobin &lt;10 g/dL in patients with cardiac disease: Reduce peginterferon alfa-2b dose by 50%; decrease ribavirin dose by 200 mg/day (patients receiving 1400 mg/day should decrease dose by 400 mg/day); may further reduce ribavirin dose by additional 200 mg/day if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     WBC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     neutrophils &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Peginterferon alfa-2b combination therapy: Refer to adult weight-based dosage reduction monotherapy for hematologic 	toxicity below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Peginterferon alfa-2b monotherapy: Refer to adult weight-based dosage reduction with combination therapy for hematologic toxicity below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL, WBC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutrophils &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Permanently discontinue peginterferon alfa-2b and ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Chronic hepatitis C:",
"      </i>",
"      Adult weight-based dosage reduction for depression or hematologic toxicity:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Peginterferon alfa-2b monotherapy:",
"     </i>",
"     Reduce to average weekly dose of 0.5 mcg/kg as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;45 kg: 20 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     46-56 kg: 25 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     57-72 kg: 30 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     73-88 kg: 40 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     89-106 kg: 50 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     107-136 kg: 64 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;137 kg: 80 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Peginterferon alfa-2b combination therapy:",
"     </i>",
"     Initially reduce to average weekly dose of  1 mcg/kg; may further reduce to average weekly dose 0.5 mcg/kg if needed as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;40 kg: 35 mcg once weekly; may further reduce to 20 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     40-50 kg: 45 mcg once weekly; may further reduce to 25 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     51-60 kg: 50 mcg once weekly; may further reduce to 30 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     61-75 kg: 64 mcg once weekly; may further reduce to 35 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     76-85 kg: 80 mcg once weekly; may further reduce to 45 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     86-104 kg: 96 mcg once weekly; may further reduce to 50 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     105-125 kg: 108 mcg once weekly; may further reduce to 64 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;125 kg: 135 mcg once weekly; may further reduce to 72 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Melanoma:",
"      </i>",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Discontinue for any of the following: Persistent or worsening severe neuropsychiatric disorders (depression, psychosis, encephalopathy), grade 4 nonhematologic toxicity, new or worsening retinopathy, new-onset ventricular arrhythmia or cardiovascular decompensation, evidence of hepatic injury (severe) or hepatic decompensation, development of hyper- or hypothyroidism or diabetes that cannot be effectively managed with medication, or inability to tolerate a dose of 1 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Temporarily withhold for any of the following: ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ECOG performance status (PS) &ge;2, nonhematologic toxicity &ge;grade 3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     May reinitiate at a reduced dose once ANC &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ECOG PS at 0-1, and nonhematologic toxicity completely resolved or improved to grade 1.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Reduced dose schedule, Weeks 1-8:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     First dose reduction (if prior dose 6 mcg/kg/week): 3 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Second dose reduction (if prior dose 3 mcg/kg/week): 2 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Third dose reduction (if prior dose 2 mcg/kg/week): 1 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Discontinue permanently if unable to tolerate 1 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Reduced dose schedule, Weeks 9-260:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     First dose reduction (if prior dose 3 mcg/kg/week): 2 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Second dose reduction (if prior dose 2 mcg/kg/week): 1 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Discontinue permanently if unable to tolerate 1 mcg/kg/week",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sylatron&trade;: 296 mcg [contains polysorbate 80, sucrose 59.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sylatron&trade;: 444 mcg [contains polysorbate 80, sucrose 59.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sylatron&trade;: 888 mcg [contains polysorbate 80, sucrose 59.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PegIntron&reg;: 50 mcg, 80 mcg, 120 mcg, 150 mcg [contains polysorbate 80, sucrose 59.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PegIntron&trade; Redipen&reg;: 50 mcg, 80 mcg, 120 mcg, 150 mcg [contains polysorbate 80, sucrose 54 mg; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     PegIntron&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133677.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133677.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     PegIntron&reg; Redipen&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133675.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133675.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Sylatron&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249397.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249397.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1029936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     PegIntron&reg; Redipen&reg;: Hold cartridge upright and press the two halves together until there is a \"click.\" Gently invert to mix; do not shake; do not reuse (single use).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PegIntron&reg; (vial):  Add 0.7 mL of SWI (supplied diluent) to the vial. Gently swirl. Do not re-enter vial after dose removed. Discard unused reconstituted portion; do not reuse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sylatron&trade; (vial): Add 0.7 mL SWI and swirl gently, resulting in the following concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     296 mcg vial: 40 mcg/0.1 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     444 mcg vial: 60 mcg/0.1 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     888 mcg vial: 120 mcg/0.1 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ: Rotate injection site; thigh, outer surface of upper arm, and abdomen are preferred injection sites; do not inject near navel or waistline; patients who are thin should only use thigh or upper arm. Do not inject into bruised, infected, irritated, red, or scarred skin. The weekly dose may be administered at bedtime to reduce flu-like symptoms. Administration volume depends on the patient's weight and peginterferon concentration used.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1029921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with any other medicines.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1029917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store Redipen&reg; at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not freeze. Once reconstituted, each product should be used immediately or may be stored for &le;24 hours at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Products do not contain preservatives; do not reuse.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1029895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PegIntron&reg;: Treatment of chronic hepatitis C (in combination with ribavirin) in patients who have compensated liver disease (FDA approved in ages &ge;3 years and adults); treatment of chronic hepatitis C (as monotherapy) in patients with compensated liver disease who have never received alfa interferons (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sylatron&trade;: Adjuvant treatment of melanoma (with microscopic or gross nodal involvement within 84 days of definitive surgical resection, including lymphadenectomy) (FDA approved in ages &ge;18 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5367712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Peginterferon alfa-2b may be confused with interferon alfa-2a, interferon alfa-2b, interferon alfa-n3, peginterferon alfa-2a",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PegIntron&reg; may be confused with Intron&reg; A, Pegasys&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Peginterferon alfa-2b may be confused with interferon alpha multi-subtype which is available in international markets",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F207008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bundle branch block, chest pain, flushing, myocardial infarction, supraventricular arrhythmia, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, chills, depression (may be severe), dizziness, emotional liability, fatigue, fever, headache, impaired concentration, insomnia, irritability, malaise, nervousness, olfactory nerve disorder, suicidal behavior (ideation/attempt/suicide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dry skin, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyper-/hypothyroidism, menstrual disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, nausea, taste perversion, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (in combination with ribavirin), neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT/AST increased, GGT increased, hepatomegaly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site inflammation/reaction, injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, musculoskeletal pain, myalgia, paresthesia, rigors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Binding antibodies (melanoma patients), diaphoresis, neutralizing antibodies, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Addiction (drug) relapse, anaphylaxis, angina, angioedema, aphthous stomatitis, aplastic anemia, arrhythmia, autoimmune thrombocytopenia (with or without purpura), bacterial infection, bipolar disorders, blindness, bronchiolitis obliterans, cardiac arrest, cardiomyopathy, cellulitis, colitis, cotton wool spots, cytopenia, diabetes mellitus, diabetic ketoacidosis, drug overdose, emphysema, encephalopathy, erythema multiforme, fungal infection, gastroenteritis, gout, hallucinations, hearing impairment/loss, hemorrhagic colitis, homicidal ideation, hyperglycemia, hyper-/hypotension, hypersensitivity reactions, hypertriglyceridemia, injection site necrosis, interstitial nephritis, interstitial pneumonitis, ischemic colitis, leukopenia, loss of consciousness, lupus-like syndrome, macular edema, mania, memory loss, migraine, myositis, nerve palsy (facial/oculomotor), optic neuritis, palpitation, pancreatitis, papilledema, pericardial effusion, peripheral neuropathy, phototoxicity, pleural effusion, pneumonia, psoriasis, psychosis, pulmonary hypertension, pulmonary infiltrates, pure red cell aplasia, renal failure, renal insufficiency, retinal artery or vein thrombosis, retinal detachment (serous), retinal hemorrhage, retinal ischemia, retinopathy, rhabdomyolysis, rheumatoid arthritis, sarcoidosis, seizure, sepsis, serum creatinine increased, Stevens-Johnson syndrome, stroke, systemic lupus erythematosus, tachycardia, thrombotic thrombocytopenic purpura, thyroiditis, toxic epidermal necrolysis, transient ischemic attack, ulcerative colitis, vasculitis, vision decrease/loss, Vogt-Koyanagi-Harada syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1029901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (including urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis) to peginterferon alfa-2b, interferon alfa, other alfa interferons, or any component; autoimmune hepatitis; decompensated liver disease (Child-Pugh score &gt;6; classes B and C). Combination therapy with ribavirin is contraindicated in pregnancy, women who may become pregnant; males with pregnant partners; hemoglobinopathies (eg, thalassemia major, sickle-cell anemia); renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10107513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); increases in serum creatinine have been reported in patients with renal impairment. Dosage adjustment may be required; discontinue if serum creatinine &gt;2 mg/dL in children. Do not use combination therapy with ribavirin in adults with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute; has not been studied in melanoma patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with a history of cardiovascular disease; hypotension, arrhythmia, bundle branch block, tachycardia, cardiomyopathy, angina pectoris, and MI have been observed with treatment. Patients with pre-existing cardiac abnormalities should have baseline ECGs prior to combination treatment with ribavirin; closely monitor patients with a history of MI or arrhythmia. Patients with a history of significant or unstable cardiac disease should not receive combination treatment with ribavirin. Discontinue treatment (permanently) for new-onset ventricular arrhythmia or cardiovascular decompensation. Use with caution in patients with debilitating conditions; interferons are commonly associated with flu-like symptoms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use caution in patients with a history of diabetes mellitus (particularly if prone to DKA). Diabetes mellitus (including new-onset type 1 diabetes) and hyperglycemia, have been reported; discontinue peginterferon alfa-2b if diabetes  cannot be effectively managed with medication.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with thyroid disorders; may cause or aggravate hyper- or hypothyroidism. Discontinue use in patients with thyroid disease who cannot be controlled with medication.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe inhibition of growth velocity, &lt;3rd percentile and affecting height and weight, was reported in 70% of pediatric patients during clinical trials on combination therapy; monitor closely; dosage adjustment may be required. After therapy, 20% continued to have severely inhibited growth; however, in majority of patients, growth velocity rates increased such that by 6 months post-treatment, weight gain stabilized to 53rd percentile (similar to predicted based on average baseline weight: 57th percentile) and height gain stabilized to 44th percentile (less than predicted based on average baseline height: 51st percentile).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dental/periodontal disorders have been reported with combination therapy; dry mouth may affect teeth and mucous membranes; instruct patients to brush teeth twice daily; encourage regular dental exams; rinse mouth after vomiting. A higher incidence in children compared to adults has been reported with fever (80% vs 46%) and vomiting (27% vs 14%).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Combination therapy with ribavirin is preferred over monotherapy for the treatment of chronic hepatitis C (combination therapy provides a better response). Safety and efficacy have not been established in patients who have received organ transplants, or are coinfected with HIV or hepatitis B. Patients with significant bridging fibrosis or cirrhosis, genotype 1 infection, or who have not responded to prior therapy, including previous pegylated interferon treatment are less likely to benefit from combination therapy with peginterferon alfa-2b and ribavirin.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1029902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May cause or aggravate severe depression or other neuropsychiatric adverse events (including suicide and suicidal ideation) in patients with and without a history of psychiatric disorder; may be irreversible; monitor closely with clinical evaluations (periodic);",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; discontinue treatment permanently with worsening or persistently severe signs/symptoms of neuropsychiatric disorders (eg, depression, encephalopathy, psychosis). Many cases resolve upon discontinuation, although some may persist. Suicidal ideation or attempts may occur more frequently in pediatric patients as compared to adults (2.4% vs 1% respectively). Addiction relapse, aggression, depression, homicidal ideation, and suicidal behavior/ideation have been observed with peginterferon alfa-2b; bipolar disorder, encephalopathy, hallucinations, mania, and psychosis have been observed with other alfa interferons. Onset may be delayed (up to 6 months after discontinuation). Higher doses may be associated with the development of encephalopathy (higher risk in elderly patients). Use with extreme caution in patients with a history of psychiatric disorders, including depression or substance abuse history. New or exacerbated neuropsychiatric or substance abuse disorders are best managed with early intervention. Drug screening and periodic health evaluation (including monitoring of psychiatric symptoms) is recommended if initiating treatment in patients with coexisting psychiatric condition or substance abuse disorders.  Monitor all patients for evidence of depression and other psychiatric symptoms; patients being treated for melanoma should be monitored for depression and psychiatric symptoms every 3 weeks during the first 8 weeks of treatment and every 6 months thereafter; discontinue treatment if psychiatric symptoms persist, worsen, or if suicidal behavior develops. All patients should continue to be monitored for 6 months after completion of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause or exacerbate autoimmune disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of autoimmune disease",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Thyroiditis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis have been reported with therapy; use with caution in patients with autoimmune disorders.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause or aggravate infectious disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of infectious disorders",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Interferon therapy is commonly associated with flu-like symptoms, including fever; rule out other causes/infection with persistent or high fever.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause or aggravate ischemic and hemorrhagic cerebrovascular events; monitor closely; discontinue treatment in patients with worsening or persistent ischemia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; cerebrovascular events have been reported in patients without risk factors for stroke.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Alpha interferons suppress bone marrow function which may result in severe cytopenias or aplastic anemia (rarely). Use with caution in patients who are chronically immunosuppressed, with low peripheral blood counts or myelosuppression, including  concurrent use of myelosuppressive therapy or at increased risk for severe anemia (eg, spherocytosis, history of GI bleeding). Dosage modification may be necessary for hematologic toxicity. Combination therapy with ribavirin may potentiate the neutropenic effects of alfa interferons. When used in combination with ribavirin, an increased incidence of anemia was observed when using ribavirin weight-based dosing, as compared to flat-dose ribavirin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Patients with chronic hepatitis C (CHC) with cirrhosis receiving alpha interferons may be at risk for hepatic decompensation and death; immediately discontinue therapy if occurs (Child-Pugh score &gt;6) or evidence of severe hepatic injury. CHC patients coinfected with HIV are at increased risk for hepatic decompensation when receiving highly active antiretroviral therapy (HAART); monitor closely. A transient increase in ALT (2-5 times above baseline) which is not associated with   liver dysfunction may occur with peginterferon alfa-2b use (for the treatment of chronic hepatitis C); may continue treatment with monitoring.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Ophthalmologic disorders (including decreased visual acuity, blindness, macular edema, retinal hemorrhages, optic neuritis, papilledema, cotton wool spots, retinal detachment [serous], and retinal artery or vein thrombosis) have occurred with peginterferon alfa-2b and/or with other alfa interferons. Prior to start of therapy, ophthalmic exams are recommended for all patients; patients with diabetic or hypertensive retinopathy should have periodic ophthalmic exams during treatment; a complete eye exam should be done promptly in patients who develop ocular symptoms. Permanently discontinue treatment with new or worsening ophthalmic disorder. May cause or aggravate dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis which can result in respiratory failure; may recur upon rechallenge with treatment; monitor closely.  Use with caution in patients with existing pulmonary disease (eg, chronic obstructive pulmonary disease). Withhold combination therapy with ribavirin for development of pulmonary infiltrate or pulmonary function impairment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Pancreatitis has been observed with alfa interferon therapy; withhold treatment for suspected pancreatitis; discontinue therapy for known pancreatitis. Hypertriglyceridemia has been reported; monitor; discontinue if persistent and severe (triglycerides &gt;1000 mg/dL), particularly if combined with symptoms of pancreatitis. Ulcerative or hemorrhagic/ischemic colitis has been observed with alfa interferons; discontinue therapy if signs of colitis (abdominal pain, bloody diarrhea, fever) develop; symptoms typically resolve within 1-3 weeks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Acute hypersensitivity reactions (urticaria, angioedema, bronchoconstriction, anaphylaxis) and cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (rarely) with alfa interferons; prompt discontinuation is recommended; transient rashes do not require interruption of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Combination treatment with ribavirin may cause birth defects and/or fetal mortality (avoid pregnancy in females and female partners of male patients); hemolytic anemia (which may worsen cardiac disease), genotoxicity, mutagenicity, and may possibly be carcinogenic. Combination therapy with ribavirin is contraindicated in pregnancy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Due to differences in dosage, patients should not change brands of interferon.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some formulations contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F206997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: Peginterferon Alfa-2b may decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: Peginterferon Alfa-2b may decrease the serum concentration of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Betaxolol (Ophthalmic); Carteolol (Ophthalmic); Timolol (Ophthalmic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: Peginterferon Alfa-2b may decrease the serum concentration of FLUoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Interferons (Alfa) may increase the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Peginterferon Alfa-2b.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telbivudine: Peginterferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C / X in combination with ribavirin (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies with pegylated interferon alfa have not been conducted. Animal reproduction studies with nonpegylated interferon alfa-2b have demonstrated abortifacient effects. Disruption of the normal menstrual cycle was also observed in animal studies; therefore, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid.",
"     <i>",
"      In vitro",
"     </i>",
"     administration studies have reported that when administered to the mother, it does not cross the placenta. Case reports of use in pregnant women are limited. The Perinatal HIV Guidelines Working Group does not recommend that peginterferon alfa be used during pregnancy. Peginterferon alfa-2b monotherapy should only be used in pregnancy when the potential benefit to the mother justifies the possible risk to the fetus.",
"     <b>",
"      [U.S. Boxed Warning]: Combination therapy with ribavirin may cause birth defects and/or fetal mortality; avoid pregnancy in females and female partners of male patients;",
"     </b>",
"     combination therapy with ribavirin is contraindicated in pregnancy. Two forms of contraception should be used during combination therapy; patients should have monthly pregnancy tests. A pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1029938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets; serum chemistries, liver function tests, renal function, triglycerides.  Clinical studies (for combination therapy) tested as follows: CBC (including hemoglobin, WBC, and platelets) and chemistries (including liver function tests and uric acid) measured at weeks 2, 4, 8, and 12, and then every 6 weeks; TSH measured every 12 weeks during treatment. ECG at baseline for patients with pre-existing cardiac abnormalities (for combination therapy with ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hepatitic C:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Serum HCV RNA levels (pretreatment, 12 and 24 weeks after therapy initiation, 24 weeks after completion of therapy).",
"     <b>",
"      Note:",
"     </b>",
"     Discontinuation of therapy may be considered after 12 weeks in patients with HCV (genotype 1) who fail to achieve an early virologic response (EVR) (defined as &ge;2-log decrease in HCV RNA compared to pretreatment) or after 24 weeks with detectable HCV RNA. Treat patients with HCV (genotypes 2,3) for 24 weeks (if tolerated) and then evaluate HCV RNA levels (Ghany, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Evaluate for depression and other psychiatric symptoms before and after initiation of therapy; patients being treated for melanoma should be monitored for depression and psychiatric symptoms every 3 weeks during the first eight weeks of treatment and every 6 months thereafter; baseline ophthalmic eye examination; periodic ophthalmic exam in patients with diabetic or hypertensive retinopathy; baseline ECG in patients with cardiac disease; serum glucose or Hb A1c (for patients with diabetes mellitus). In combination therapy with ribavirin, pregnancy tests (for women of childbearing age who are receiving treatment or who have male partners who are receiving treatment), continue monthly up to 6 months after discontinuation of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1029922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inducer of the innate antiviral immune response; binds to the human type 1 interferon receptor which activates multiple intracellular signal transduction pathways, resulting in suppression of cell proliferation, immunomodulating activities (such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells), and inhibition of virus replication in virus-infected cells",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1029924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Peginterferon alfa-2b has a prolonged duration of effect relative to interferon alfa-2b and a reduced renal clearance (sevenfold lower). Data in children similar to adult values.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Increases with chronic dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Chronic hepatitis C: ~40 hours (range: 22-60 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 15-44 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (30%); clearance reduced in renal impairment by 17% in moderate dysfunction, 44% in severe dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1029939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/8/30854?source=see_link\">",
"      see \"Pegylated interferon (peginterferon) alfa-2b: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of peginterferon alfa-2b. Do not operate heavy machinery while on therapy since changes in mental status may occur; may cause dry mouth.   Report any signs of depression or suicidal ideation, breathing problems, bleeding or easy bruising, or vision changes to your physician. If also taking ribavirin, avoid pregnancy (female patients or female partners of male patients).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38088/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, \"ACOG Practice Bulletin No. 86: Viral Hepatitis in Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(4):941-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38088/abstract-text/17906043/pubmed\" id=\"17906043\" target=\"_blank\">",
"        17906043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38088/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38088/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dienstag JL and McHutchison JG, \"American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(1):225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38088/abstract-text/16401485/pubmed\" id=\"16401485\" target=\"_blank\">",
"        16401485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, \"Diagnosis, Management, and Treatment of Hepatitis C: An Update,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38088/abstract-text/19330875/pubmed\" id=\"19330875\" target=\"_blank\">",
"        19330875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar AR, Hale TW, and Moke RE, &ldquo;Transfer of Interferon Alfa Into Human Breast Milk,&rdquo;",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2000, 16:226-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lebon P, Girard S, Th&eacute;pot F, et al, \"The Presence of Alpha-Interferon in Human Amniotic Fluid,\"",
"      <i>",
"       J Gen Virol",
"      </i>",
"      , 1982, 59(Pt 2):393-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38088/abstract-text/6176680/pubmed\" id=\"6176680\" target=\"_blank\">",
"        6176680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\" April 29, 2009, 1-90. Available at:",
"      <a href=\"file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf\">",
"       file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waysbort A, Giroux M, Mansat V, et al, \"Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1993, 37(6):1232-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/12/38088/abstract-text/8328774/pubmed\" id=\"8328774\" target=\"_blank\">",
"        8328774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15557 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38088=[""].join("\n");
var outline_f37_12_38088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709198\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206967\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029894\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029929\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206945\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206930\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874942\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029936\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029921\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029917\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029895\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5367712\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207008\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029901\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10107513\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029902\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206997\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206938\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206940\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206952\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029938\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029922\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029924\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1029939\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15557|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2b: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/8/30854?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2b: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_12_38089="Ulnar neuropathy at the elbow and wrist";
var content_f37_12_38089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ulnar neuropathy at the elbow and wrist",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/12/38089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/12/38089/contributors\">",
"     Timothy J Doherty, MD, PhD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/12/38089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/12/38089/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/12/38089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/12/38089/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/12/38089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19484182\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Entrapment or compressive neuropathies are common problems that may lead to functional impairment and disability of the upper limb due to weakness, loss of dexterity, altered sensation, and sometimes pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/1\">",
"     1",
"    </a>",
"    ]. Ulnar neuropathy, especially at the elbow, is a common focal neuropathy affecting the upper extremity and is second in frequency only to entrapment of the median nerve at the wrist (the carpal tunnel syndrome). Accurate and timely diagnosis is important for clarifying the presence and severity of nerve injury, determining prognosis, avoiding unnecessary investigation or surgery, and establishing a treatment plan.",
"   </p>",
"   <p>",
"    This topic will review the clinical features, diagnosis, and treatment of ulnar neuropathy at the elbow and wrist. Other focal neuropathies affecting the arm and hand are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=see_link\">",
"     \"Brachial plexus syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19484189\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ulnar nerve is derived from the anterior rami of the C8 and T1 spinal nerves with a variable contribution from C7 (",
"    <a class=\"graphic graphic_figure graphicRef50576 \" href=\"mobipreview.htm?34/25/35222\">",
"     figure 1",
"    </a>",
"    ). These contributing fibers are initially carried in the lower trunk and medial cord of the brachial plexus with the ulnar nerve arising in the proximal axilla.",
"   </p>",
"   <p>",
"    In the upper arm, the ulnar nerve lies in close proximity to the brachial artery and the median nerve. It has no branches above the elbow (",
"    <a class=\"graphic graphic_figure graphicRef75124 \" href=\"mobipreview.htm?22/56/23428\">",
"     figure 2",
"    </a>",
"    ). This anatomic feature can lead to challenges in localizing proximal ulnar nerve lesions in some cases.",
"   </p>",
"   <p>",
"    At the mid-point of the upper arm, the ulnar nerve pierces the medial intermuscular septum (the arcade of Struthers) and heads posteriorly where it lies close to the humerus and the medial head of the triceps brachii muscle and tendon. Distal to this segment, the ulnar nerve travels within the retrocondylar groove of the elbow, posteromedial to the medial epicondyle. As the nerve exits the groove it passes under the aponeurotic arch of the flexor carpi ulnaris muscle, also called the humeroulnar arcade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/2\">",
"     2",
"    </a>",
"    ], which is formed by attachments of this muscle to the medial epicondyle and olecranon (",
"    <a class=\"graphic graphic_figure graphicRef68935 \" href=\"mobipreview.htm?33/62/34785\">",
"     figure 3",
"    </a>",
"    ). The proximal edge of the arcade lies about 1 to 2 cm distal to a line joining the medal epicondyle and olecranon. This is an important structure clinically because it is often implicated as the cause of compressive ulnar neuropathy at the elbow (UNE).",
"   </p>",
"   <p>",
"    After passing underneath the arch, the ulnar nerve travels within the cubital tunnel through the two heads of the flexor carpi ulnaris muscle. The roof of the cubital tunnel is the humeroulnar arcade proximally, and the substance of the two heads of the flexor carpi ulnaris muscle distally. The floor of the tunnel is composed of the medial elbow ligaments proximally and the deep fibers of the flexor carpi ulnaris muscle more distally. The nerve then pierces the aponeurosis lining the deep heads of the flexor carpi ulnaris and runs between the tendons and muscle planes of the medial forearm to the wrist.",
"   </p>",
"   <p>",
"    The ulnar nerve gives off motor branches to the flexor carpi ulnaris in the proximal forearm, distal to the medial epicondyle and just proximal to or within the cubital tunnel (",
"    <a class=\"graphic graphic_figure graphicRef75124 \" href=\"mobipreview.htm?22/56/23428\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/3\">",
"     3",
"    </a>",
"    ]. The branch to the ulnar-innervated portion of the flexor digitorum profundus (supplying digits four and five) is given off more distally within the cubital tunnel. The palmar cutaneous branch arises in the mid-forearm and runs distally over the volar aspect of the forearm and wrist without passing through Guyon's canal. It supplies the cutaneous territory over the proximal border of the ulnar portion of the palm (",
"    <a class=\"graphic graphic_figure graphicRef76075 \" href=\"mobipreview.htm?23/56/24448\">",
"     figure 4",
"    </a>",
"    ). The dorsal cutaneous branch is given off more distally, about 5 cm proximal to the wrist, and courses dorsally around the ulna to supply the ulnar side of the dorsum of the hand and dorsal surfaces of the fifth and ulnar half of the fourth digit (",
"    <a class=\"graphic graphic_figure graphicRef76075 \" href=\"mobipreview.htm?23/56/24448\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At the wrist, the ulnar nerve passes through Guyon's canal (along with the ulnar artery), the floor of which is formed by the transverse carpal ligament and pisohamate ligament. The roof of Guyon&rsquo;s canal consists of the palmar fascia and the palmaris brevis muscle. The ulnar nerve then divides into the superficial and deep terminal branches (",
"    <a class=\"graphic graphic_figure graphicRef57601 \" href=\"mobipreview.htm?15/0/15364\">",
"     figure 5",
"    </a>",
"    ). In the hand, after giving off a branch to the palmaris brevis muscle, the superficial terminal branch supplies the cutaneous ulnar border of the palm and then divides into two digital branches that innervate the palmar or volar surfaces of the fifth and ulnar half of the fourth digit (",
"    <a class=\"graphic graphic_figure graphicRef76075 \" href=\"mobipreview.htm?23/56/24448\">",
"     figure 4",
"    </a>",
"    ). The deep branch pierces and innervates the opponens digiti muscle and then gives off a branch to the remaining hypothenar muscles just after emerging from Guyon's canal. In the palm, the deep branch innervates all of the interossei and the third and fourth lumbricals (",
"    <a class=\"graphic graphic_figure graphicRef75124 \" href=\"mobipreview.htm?22/56/23428\">",
"     figure 2",
"    </a>",
"    ). It then terminates in the thenar eminence where it supplies the adductor pollicis and variable portions of the flexor pollicis brevis muscles.",
"   </p>",
"   <p>",
"    The anatomy of the ulnar nerve at the elbow requires special mention, given the close relationship between the musculoskeletal structures of this region and clinical entity of UNE. With elbow flexion, the distance between the medial epicondyle and olecranon increases by up to 1 cm. This results in tightening of the humeroulnar arcade of the flexor carpi ulnaris over the nerve (",
"    <a class=\"graphic graphic_figure graphicRef57076 \" href=\"mobipreview.htm?20/2/20514\">",
"     figure 6",
"    </a>",
"    ). Also upon flexion, the medial elbow ligaments bulge and flatten the floor of the normally deep retrocondylar groove, while the medial head of the triceps muscle pushes the nerve posteriorly. With complete elbow flexion the nerve is stretched taught around the medial epicondyle, whereas in extension there is redundant length in the nerve allowing for freedom of movement. Intraoperative pressure recordings in patients with ulnar neuropathy have documented increased pressure under the humeroulnar arcade during elbow flexion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19484196\">",
"    <span class=\"h2\">",
"     Sites of ulnar nerve lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common site of focal ulnar entrapment or compression is at the elbow, followed by the wrist.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulnar neuropathy at the elbow was first identified in 1878 within a description of operative treatment for ulnar neuropathy following remote elbow fracture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/5\">",
"       5",
"      </a>",
"      ]. Broca and Mouchet applied the term &ldquo;tardy ulnar palsy&rdquo; to this syndrome in 1899 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/6\">",
"       6",
"      </a>",
"      ]. This term has subsequently been used inappropriately to describe all cases of UNE (as opposed to only those following remote bony injury). Entrapment under the humeroulnar arcade was described in 1922 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/7\">",
"       7",
"      </a>",
"      ], in what later became known as the cubital tunnel syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/8\">",
"       8",
"      </a>",
"      ]. This term is also often used inappropriately to describe all causes of UNE. However, the clinical features of ulnar neuropathy and the available diagnostic tools are often incapable of localizing lesions at the elbow precisely. Therefore, the more generic term UNE is preferred, as it does not imply a specific site of compression (eg, the cubital tunnel). However, it is important to understand the anatomic structures around the elbow in terms of their role in the pathophysiology of ulnar nerve injury.",
"     </li>",
"     <li>",
"      The main distal trunk of the ulnar nerve and its two branches, the superficial sensory branch and deep motor branch, can be injured around the wrist, although ulnar nerve injury at the wrist is less common than at the elbow. This is mainly owing to the relationship of the ulnar nerve to the musculoskeletal structures at the elbow. The etiology of distal ulnar lesions can be divided into intrinsic and extrinsic causes. The extrinsic causes include lacerations, and direct, often repetitive trauma, such as repetitive use of tools in the workplace [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/9\">",
"       9",
"      </a>",
"      ], or propulsion of a manual wheelchair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/10\">",
"       10",
"      </a>",
"      ]. A number of cases have been reported in cyclists as a result of direct pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. Intrinsic causes include ganglia arising from the wrist joint or intraneural ganglia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ulnar nerve, sometimes in combination with the median and radial nerves, can also be compressed in the axilla or upper arm by external structures (eg, crutches, tourniquets, pressure during sleep). However, such injuries to the ulnar nerve are rather uncommon owing to its reasonably protected position in the upper arm. Compression of the ulnar nerve by internal structures (aneurysms, hematomas, compartment syndromes, bony fragments from humeral shaft fractures) also can result in proximal ulnar nerve lesions. There are case reports of entrapment by the medial intramuscular septum (arcade of Struthers) as the ulnar passes through this structure when traversing from the anterior to posterior compartment of the arm, but these presentations are rare in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Because there are no motor or sensory branches given off by the ulnar nerve in the upper arm, the neurologic deficits related to proximal ulnar nerve injuries in the upper arm or axilla are identical to those caused by more distal ulnar nerve lesions at the elbow. Therefore, one is dependent on the clinical scenario, the presence of proximal pain or a mass, or the involvement of other nerves (median and radial) to aid in localization.",
"   </p>",
"   <p>",
"    Distal to the elbow, the ulnar nerve rarely can be compressed within the body of flexor carpi ulnaris muscle or where it exits through the deep flexor-pronator aponeurosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26073271\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulnar neuropathy at the elbow (UNE) is the second most commonly diagnosed focal neuropathy, surpassed only by median neuropathy at the wrist. In a study from Italy, the raw annual incidence of UNE was 24.7 cases per 100,000 person years, and the incidence in men was nearly double that of women (32.7 versus 17.2 per 100,000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/20\">",
"     20",
"    </a>",
"    ]. In another study from the United Kingdom that analyzed a large general practice database, the annual incidence of ulnar neuropathy (including all anatomic locations) for men and women was 25.2 and 18.9 per 100,000 respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for ulnar neuropathy are poorly defined because the available data are retrospective, limited, and conflicting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a hospital based case-control study that compared 110 patients who had surgical treatment for UNE with 192 control patients treated for cervical or lumbar herniated disc, risk factors for UNE included smoking, educational level, and work experience; in contrast, gender, body mass index, alcohol consumption, elbow trauma, diabetes, and hypertension were not risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another retrospective study compared patients with electrodiagnostic studies confirming UNE (n = 112) to patients whose studies excluded UNE (n = 104) and identified male sex and increasing age as risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19484203\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulnar lesions at the elbow typically present with numbness and tingling in the fourth and fifth digits, elbow pain, nocturnal awakening, and worsening of symptoms with elbow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repeated wrist flexion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/3\">",
"     3",
"    </a>",
"    ]. Ulnar lesions at the wrist typically present with hand weakness and atrophy, loss of dexterity, and variable sensory involvement as outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87963056\">",
"    <span class=\"h2\">",
"     Ulnar neuropathy at the elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of ulnar neuropathy at the elbow are readily understood based upon knowledge of the motor and sensory distribution of the ulnar nerve and its major branches. Sensory symptoms of numbness or paresthesiae in the ulnar nerve distribution are the most frequent initial complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/1\">",
"     1",
"    </a>",
"    ]. It is the author&rsquo;s impression that patients usually experience the sensory symptoms over the volar aspect of the fourth and fifth digits and ulnar aspect of the hand. The presence of sensory symptoms in the dorsal ulnar or palmar cutaneous territory (",
"    <a class=\"graphic graphic_figure graphicRef76075 \" href=\"mobipreview.htm?23/56/24448\">",
"     figure 4",
"    </a>",
"    ) is helpful in localizing the lesion proximal to the distal forearm or wrist, but these complaints are not always present. As an example, in one study of 25 patients with UNE, the distribution of sensory symptoms involved the digital terminal branches, the palmar cutaneous territory, and the dorsal cutaneous territory in 92, 80, and 72 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/24\">",
"     24",
"    </a>",
"    ]. Some patients with severe and persistent numbness will report splitting of the ring finger. Medial elbow pain or aching is common and many patients report referred pain along the medial forearm. However, true paresthesia or numbness of the medial forearm in the distribution of the medial cutaneous nerve of the forearm should alert the clinician to a more proximal lesion of the C8 or T1 roots, or to a lesion of the lower trunk or medial cord of the brachial plexus.",
"   </p>",
"   <p>",
"    Sensory symptoms from UNE are often brought on by sustained elbow flexion (eg, when talking on the phone or lying on one's side with the elbow flexed). Symptoms can also be provoked by leaning on the elbow or when performing activity that requires sustained or repetitive grip, or repeated forearm pronation and supination.",
"   </p>",
"   <p>",
"    Motor symptoms in UNE are overall less common than sensory symptoms, but range from mild weakness of intrinsic hand muscles to severe wasting and claw hand deformity (",
"    <a class=\"graphic graphic_picture graphicRef65510 \" href=\"mobipreview.htm?22/36/23107\">",
"     picture 1",
"    </a>",
"    ). Some patients will report only mild weakness and clumsiness of the hand during activities requiring dexterity and fine control such as buttoning or typing. Loss of dexterity due to ulnar neuropathy is usually indicative of weakness of the intrinsic hand muscles (ie, the lumbricals and interossei), in contrast to mild median nerve injury, where loss of dexterity is most often related to sensory loss. More significant involvement of the ulnar-innervated forearm muscles, primarily flexor digitorum profundus to the fourth and fifth digits, leads to complaints of grip weakness and difficulty lifting and carrying. In a report of 25 patients with UNE, weakness of the first dorsal interosseous, abductor digiti minimi, flexor digitorum profundus, and flexor carpi ulnaris was present in 84, 76, 56, and 20 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/24\">",
"     24",
"    </a>",
"    ]. This distribution is consistent with our clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87963063\">",
"    <span class=\"h2\">",
"     Ulnar neuropathy at the wrist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulnar lesions at the wrist typically present with hand weakness and atrophy, loss of dexterity, and variable sensory involvement. The extent of clawing of digits four and five (",
"    <a class=\"graphic graphic_picture graphicRef65510 \" href=\"mobipreview.htm?22/36/23107\">",
"     picture 1",
"    </a>",
"    ) can be worse with lesions at the wrist than at the elbow as a result of sparing of the flexor digitorum profundus and weakness of the third and fourth lumbricals.",
"   </p>",
"   <p>",
"    Injury to the terminal branches of the ulnar nerve at the wrist (",
"    <a class=\"graphic graphic_figure graphicRef57601 \" href=\"mobipreview.htm?15/0/15364\">",
"     figure 5",
"    </a>",
"    ) is often divided into four sites and their associated clinical scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1) Injury to the main trunk of the nerve proximal to or within Guyon's canal. These lesions will produce sensory symptoms in the distribution of the superficial terminal branches, and motor involvement of all ulnar innervated intrinsic hand muscles (hypothenar muscles, interossei, lumbricals three and four, and the adductor pollicis).",
"     </li>",
"     <li>",
"      2) Injury to the deep terminal motor branch of the ulnar nerve proximal to the branches supplying the hypothenar muscles. This will again produce motor symptoms in all of the ulnar-innervated intrinsic hand muscles but no sensory symptoms.",
"     </li>",
"     <li>",
"      3) Injury to the deep motor branch distal to the hypothenar muscles will spare the hypothenar muscles and result in no sensory symptoms, but the remainder of the ulnar-innervated intrinsic hand muscles will be affected.",
"     </li>",
"     <li>",
"      4) Injury to the superficial terminal branch supplying the superficial sensory branches will result in sensory involvement of the digital branches but no motor involvement. Clinically detectable dysfunction of the palmaris brevis muscle innervated by this branch is unlikely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While this classification makes sense anatomically, the actual anatomic site of the lesion does not reliably correlate with the clinical features. As an example, a lesion within Guyon's canal can spare the hypothenar branch or deep motor branch. This is a result of the fascicular arrangement of the nerve and the typically incomplete involvement of all fascicles at a given level, especially with lesions of the main trunk of the nerve within Guyon's canal. Nevertheless, this approach provides a framework for clinical assessment prior to further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19485578\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of UNE or ulnar neuropathy at the wrist should be reasonably straightforward from a careful history, clinical examination, and knowledge of the anatomy underlying the peripheral motor and sensory symptoms. When typical symptoms of intermittent numbness and paresthesia in the fourth and fifth digits are present, often brought on by pressure or flexion of the elbow, the clinical diagnosis of UNE is likely. However, the diagnosis can be challenging due to the potential for selective fascicular involvement of the motor and sensory fibers and the presence of comorbid conditions such as carpal tunnel syndrome, generalized polyneuropathy, radiculopathy, or referred pain from musculoskeletal problems such as tendonitis. Therefore, further diagnostic tools are often required as discussed below. In most cases, the diagnosis of ulnar neuropathy can be confirmed by electrodiagnostic testing or imaging when suspected on the basis of clinical symptoms or signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26073279\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of UNE and ulnar neuropathy at the wrist includes proximal lesions of the C8 or T1 roots and the lower",
"    <span class=\"nowrap\">",
"     trunk/medial",
"    </span>",
"    cord of the brachial plexus (",
"    <a class=\"graphic graphic_figure graphicRef50576 \" href=\"mobipreview.htm?34/25/35222\">",
"     figure 1",
"    </a>",
"    ). These disorders often differ clinically with sensory involvement extending proximal to the wrist in the distribution of the medial cutaneous nerve of the forearm, and motor involvement of non-ulnar innervated muscles such as flexor pollicis longus, extensor pollicis, and the thenar muscles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=see_link\">",
"     \"Brachial plexus syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ulnar lesions in the upper arm can mimic ulnar lesions at the elbow or wrist, and one is often dependent on the clinical scenario, or the presence of motor and sensory deficits secondary to co-existing median or radial nerve injuries to aid in localization. Electrodiagnosis can be extremely valuable in ruling out UNE or ulnar injury at the wrist and examining for the presence of other lesions of the peripheral nervous system.",
"   </p>",
"   <p>",
"    Central lesions can rarely present as UNE. Weakness and wasting in the ulnar distribution in the absence of sensory symptoms is suggestive of amyotrophic lateral sclerosis or the more benign monomelic amyotrophic form of motor neuron disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Monomelic amyotrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical syringomyelia can present with focal wasting of intrinsic hand muscles; however, the motor involvement is rarely confined to the ulnar distribution and the sensory symptoms are more generalized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link&amp;anchor=H33#H33\">",
"     \"Disorders affecting the spinal cord\", section on 'Syringomyelia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small subcortical infarcts may present with focal hand weakness, but the deficits are not typically confined to the ulnar distribution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170956430\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination should include a careful inspection of the limb for any evidence of muscle wasting, particularly in the interossei and hypothenar eminence. It is important to make side-to-side comparisons, looking for any asymmetry. Deformity of the elbow or wrist may be associated with previous trauma or degenerative or inflammatory arthritis. The ulnar nerve should be palpated along its course in the retrocondylar groove and above the elbow for any evidence of masses or swelling. In the author&rsquo;s clinical experience, it is useful to examine for the presence of ulnar nerve subluxation laterally over the medial epicondyle; this is especially relevant when present only on the affected side. Motor examination should focus on a careful assessment of the ulnar-innervated intrinsic and extrinsic muscles. An assessment of radial- and median-innervated forearm and hand muscles is necessary to exclude more proximal lesions of the C8 or T1 roots, the brachial plexus, or a more generalized motor neuronopathy.",
"   </p>",
"   <p>",
"    Sensation should be tested to pinprick and light touch in all three major sensory territories (digital branches and palmar and dorsal cutaneous nerves). The presence of deficits in the palmar and dorsal cutaneous territories are helpful in ruling in a lesion proximal to the distal forearm, but their absence does not rule out UNE as some patients may experience deficits in only the digital tips of the fourth and fifth digits or may have no demonstrable sensory loss resulting from selective fascicular injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170956483\">",
"    <span class=\"h2\">",
"     Provocative tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of provocative maneuvers for ulnar neuropathy, including Tinel&rsquo;s test, elbow flexion, pressure (compression), combined elbow flexion with pressure, and palpation for local nerve tenderness and nerve thickening. These tests can be helpful when interpreted in the proper clinical context. However, the sensitivity and specificity of these provocative tests for ulnar neuropathy appears to be suboptimal.",
"   </p>",
"   <p>",
"    The Tinel test at the elbow is performed by firm percussion over the ulnar nerve in the ulnar groove and a bit further distally over the cubital tunnel. Percussion over Guyon&rsquo;s canal can be performed for assessment of ulnar neuropathy at the wrist. In addition, percussion can be applied in the upper arm 7 to 10 cm proximal to the medial epicondyle to evaluate for ulnar neuropathy along the medial intermuscular septum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/19\">",
"     19",
"    </a>",
"    ]. The elbow flexion test involves sustained maximal elbow flexion for one minute with the wrist in a neutral position, while the pressure test is carried out by applying sustained manual pressure over the ulnar nerve in the ulnar groove. These tests are considered positive when they result in paresthesia or pain in ulnar-innervated regions of the hand, particularly the fourth and fifth digits (",
"    <a class=\"graphic graphic_figure graphicRef76075 \" href=\"mobipreview.htm?23/56/24448\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The available data are limited and inconsistent but suggest that clinical utility of provocative tests for ulnar neuropathy is inadequate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the highest quality prospective studies evaluated 192 patients suspected of having UNE, including 137 patients with a final diagnosis of UNE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/25\">",
"       25",
"      </a>",
"      ]. The sensitivities and specificities were as follows: Tinel&rsquo;s test, 62 and 53 percent; combined elbow flexion, 61 and 40 percent; palpation for nerve thickening, 28 and 87 percent; and palpation for nerve tenderness, 32 and 80 percent. Thus, none of the evaluated provocative tests had both good sensitivity and good specificity. Combinations of two or more tests did not improve the diagnostic accuracy because of a substantial loss of specificity.",
"     </li>",
"     <li>",
"      In contrast, another prospective study compared a group of 32 subjects who had clinical and electrophysiologic evidence of UNE with 33 control subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/26\">",
"       26",
"      </a>",
"      ]. The sensitivities were good for Tinel&rsquo;s test (70 percent) and the combined pressure flexion test (91 percent), but sensitivities were low for elbow flexion (32 percent) and pressure provocation (55 percent). While specificities were high (95 to 99 percent) for all tests, this latter observation likely relates to the severity of the group examined in this small study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical experience suggests that the presence of a Tinel's sign with percussion of the ulnar nerve at the elbow is common in asymptomatic individuals. However, its presence unilaterally with light tapping of the nerve can be helpful. Some investigators stress that Tinel&rsquo;s test should be considered positive only when there is marked tingling and local sensitivity on light tapping or palpation, since mild paresthesia are often elicited in normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19484217\">",
"    <span class=\"h2\">",
"     Electrodiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic testing, typically involving nerve conduction studies and sometimes needle electromyography (EMG), is a standard part of the evaluation for ulnar neuropathy, even in seemingly straightforward cases where suspicion is high. These tests are useful to confirm the diagnosis, establish baseline results, and rule out other potential causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/28\">",
"     28",
"    </a>",
"    ]. They are particularly helpful when the clinical presentation is not straightforward, such as in cases complicated by associated musculoskeletal pain, co-existing carpal tunnel syndrome, or radiculopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529565\">",
"    <span class=\"h3\">",
"     Ulnar neuropathy at the elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;In terms of UNE, the goal of electrodiagnostic studies is to localize the lesion to the ulnar nerve at the elbow, determine the character and severity of the injury, aid in prognosis, and examine for the presence or absence of alternative diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/28\">",
"     28",
"    </a>",
"    ]. Typically, motor nerve conduction studies are obtained, recording from either the hypothenar eminence or first dorsal interosseous muscles, with stimulation at the wrist, below the elbow, and above the elbow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/29\">",
"     29",
"    </a>",
"    ]. The amplitude of the maximum compound muscle action potential in response to the distal site of stimulation at the wrist is a reasonable indication of the number of functioning motor axons, at least with acute or subacute presentations prior to reinnervation via collateral reinnervation. Focal slowing or conduction block across the elbow provides the most compelling evidence of a localized lesion (",
"    <a class=\"graphic graphic_figure graphicRef67364 \" href=\"mobipreview.htm?6/37/6751\">",
"     figure 7",
"    </a>",
"    ). In the absence of focal conduction block or slowing, one cannot be definite as to the presence of UNE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors are proponents of the short segment incremental study, or so-called &ldquo;inching&rdquo;, an electrodiagnostic technique that is performed by stimulating short intervals of the ulnar nerve, typically at successive 1 cm increments, in order to more precisely localize the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. As an example, one such study reported that short segment inching technique distinguished focal slowing in the retrocondylar groove from slowing in the humeroulnar",
"    <span class=\"nowrap\">",
"     arcade/cubital",
"    </span>",
"    tunnel in 80 percent of cases based upon comparison to intraoperative electrodiagnostic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensory nerve conduction studies that record the sensory nerve action potential from the ulnar-innervated fifth digit provide evidence of sensory axonal involvement. Segmental sensory studies can also be used to look for evidence of conduction slowing across the elbow. However, these studies can be technically challenging in the setting of moderate to severe axon loss. The presence of a normal or absent dorsal ulnar cutaneous sensory response is helpful in localizing lesions to the elbow or wrist, especially when the response is normal on the unaffected side.",
"   </p>",
"   <p>",
"    Routine nerve conduction studies for the diagnosis of UNE typically include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ulnar motor study recording from the abductor digiti minimi, stimulating at the wrist, below the elbow, and above the elbow with the elbow in the flexed position",
"     </li>",
"     <li>",
"      Median motor study recording from the abductor pollicis brevis while stimulating at the wrist and elbow",
"     </li>",
"     <li>",
"      Ulnar sensory response recording digit five while stimulating at the wrist",
"     </li>",
"     <li>",
"      Median sensory response recording digit two or three while stimulating at the wrist",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional comparison studies should be considered if the ulnar neuropathy is not localizable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Repeat motor studies recording the first dorsal interosseous",
"     </li>",
"     <li>",
"      Motor inching across the elbow",
"     </li>",
"     <li>",
"      Sensory or mixed-nerve studies across the elbow",
"     </li>",
"     <li>",
"      Recording bilateral dorsal ulnar cutaneous sensory nerve action potential",
"     </li>",
"     <li>",
"      Recording bilateral medial antebrachial cutaneous sensory nerve action potential if sensory loss extends above the wrist on clinical examination, or if there is a suggestion of lower brachial plexus lesion by history",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Needle electromyography (EMG) is helpful in determining the presence or absence of acute or chronic motor axonal involvement. In particular, the presence on needle EMG of abnormalities in the ulnar innervated forearm muscles, and the absence of abnormalities in the median and radial distribution, is helpful in localizing a lesion proximal to wrist or forearm. However, one cannot definitively exclude a UNE when ulnar-innervated forearm muscles are normal due to possible sparing of the fascicles supplying these muscles.",
"   </p>",
"   <p>",
"    One suggested protocol for EMG evaluation of suspected UNE involves needle examination of the following ulnar-innervated muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distal to the wrist: first dorsal interosseous or abductor digiti minimi",
"     </li>",
"     <li>",
"      In the forearm: flexor digitorum profundus (digit five) and flexor carpi ulnaris",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional muscles are investigated if any of the ulnar muscles are abnormal to rule out a lower brachial plexopathy, polyneuropathy, or radiculopathy of C8 or T1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two or more non-ulnar lower",
"      <span class=\"nowrap\">",
"       trunk/C8-T1",
"      </span>",
"      muscles (eg, abductor pollicis brevis, flexor pollicis longus, extensor indicis proprius)",
"     </li>",
"     <li>",
"      C8 and T1 paraspinal muscles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The precise sensitivities and specificities of electrodiagnostic tests for UNE are uncertain because existing studies are generally limited by small numbers of patients with known ulnar neuropathy, as opposed to examination of a larger group of patients that may or may not have the disorder. These reports are also inconsistent with respect to the relative utility of motor conduction, sensory conduction, and mixed motor-sensory conduction studies for UNE.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest studies evaluated 109 affected arms (n = 102 patients) with a clinical diagnosis of UNE, including 38 arms with purely sensory signs and 71 arms with both sensory and motor signs (none had motor signs alone) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/34\">",
"       34",
"      </a>",
"      ]. The sensitivity of motor conduction studies for localizing the ulnar neuropathy at the elbow was 78 percent, and there was no significant difference in sensitivity between those who had sensory signs only compared with those who had both sensory and motor signs (79 versus 76 percent).",
"     </li>",
"     <li>",
"      In a report that evaluated 21 patients with suspected ulnar neuropathy, the sensitivities for the diagnosis of UNE based upon motor conduction slowing across the elbow when recording from first dorsal interosseous and abductor digiti minimi (quinti) were 81 and 71 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/35\">",
"       35",
"      </a>",
"      ]. In contrast, the sensitivity of the ulnar mixed motor-sensory study was only 57 percent.",
"     </li>",
"     <li>",
"      In a case-control study, 43 patients referred for evaluation of ulnar neuropathy were divided into those with UNE considered either clinically definite (n = 21) or possible (n = 22) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/36\">",
"       36",
"      </a>",
"      ]. Based upon segmental motor slowing, the diagnostic yield was 67 percent in the definite group and only 9 percent in the possible group. These values were increased to 86 percent and 68 percent, respectively, by the addition of segmental sensory or mixed nerve studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529572\">",
"    <span class=\"h3\">",
"     Ulnar neuropathy at the wrist",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrodiagnostic localization of ulnar neuropathy at the wrist is based upon the detection of focal motor or sensory nerve conduction slowing or block with stimulation at the wrist and no evidence of more proximal block or slowing. A normal dorsal ulnar cutaneous sensory potential is helpful in ruling out more proximal lesions, as is the presence of normal needle EMG findings in the flexor carpi ulnaris and flexor digitorum profundus muscles. Unfortunately, in some cases where there is only chronic motor and sensory involvement affecting ulnar-innervated intrinsic hand muscles and the digital sensory branches, there is no way to be precise in electrodiagnostic localization.",
"   </p>",
"   <p>",
"    Routine nerve conduction studies for the diagnosis of ulnar neuropathy at the wrist typically include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ulnar motor study recording from the abductor digiti minimi while stimulating at the wrist, below the elbow, and above the elbow, with the elbow in the flexed position",
"     </li>",
"     <li>",
"      Ulnar motor study (bilateral) recording from the first dorsal interosseous while stimulating at the wrist",
"     </li>",
"     <li>",
"      Median motor study recording from the abductor pollicis brevis while stimulating at the wrist and elbow",
"     </li>",
"     <li>",
"      Ulnar sensory response recording digit five while stimulating at the wrist",
"     </li>",
"     <li>",
"      Median sensory response recording digit two or three while stimulating at the wrist",
"     </li>",
"     <li>",
"      Dorsal ulnar cutaneous sensory response (bilateral)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One suggested protocol for needle EMG evaluation of suspected ulnar neuropathy at the wrist involves examination of the following ulnar-innervated muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deep palmar: first dorsal interosseous",
"     </li>",
"     <li>",
"      Hypothenar: abductor digiti minimi",
"     </li>",
"     <li>",
"      Forearm: flexor carpi ulnaris and flexor digitorum profundus (digit five)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional muscles are investigated if any of the ulnar muscles are abnormal to rule out a lower brachial plexopathy, polyneuropathy, or radiculopathy of C8 or T1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two or more non-ulnar lower",
"      <span class=\"nowrap\">",
"       trunk/C8-T1",
"      </span>",
"      muscles (eg, abductor pollicis brevis, flexor pollicis longus, extensor indicis proprius)",
"     </li>",
"     <li>",
"      C8 and T1 paraspinal muscles",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19484224\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both MRI and ultrasonography are useful diagnostic tests for UNE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. On ultrasonography, features of UNE include thickening of the nerve and altered echogenicity. On MRI, UNE is indicated by nerve enlargement and increased signal intensity on T2-weighted or short T1 inversion recovery (STIR) sequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/38\">",
"     38",
"    </a>",
"    ]. In one prospective study examining a group of 27 patients (35 arms) meeting typical clinical criteria, increased signal of the ulnar nerve on MRI was found on STIR sequences in 97 percent of cases and enlargement of the nerve in 74 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/42\">",
"     42",
"    </a>",
"    ]. Electrodiagnostic testing in this study was positive in 77 percent of cases. Another study of 52 patients with clinical evidence of UNE reported a similarly high sensitivity of MRI for UNE in comparison to nerve conduction studies (90 versus 65 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/43\">",
"     43",
"    </a>",
"    ]. The MRI was particularly useful for those with nonlocalizing electrodiagnostic studies (n = 19), where MRI detected evidence of UNE in 16 patients (84 percent).",
"   </p>",
"   <p>",
"    The usefulness of ultrasonography for diagnosis of UNE was demonstrated in a prospective study that evaluated 123 patients who had suspected UNE, with a final diagnosis of UNE in 84 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/44\">",
"     44",
"    </a>",
"    ]. The sonographic diagnosis of UNE, based upon the presence of a larger nerve diameter in comparison to control patients, yielded a sensitivity and specificity of 80 and 91 percent compared with the diagnosis made by standard clinical and electrophysiologic criteria. Among 20 cases with nonlocalizing electrodiagnostic findings of ulnar neuropathy but clear clinical evidence of UNE, ultrasonography confirmed the diagnosis of UNE in 17 (85 percent); in 37 patients who had evidence of motor conduction velocity slowing across the elbow without conduction block, ultrasonography confirmed the diagnosis of UNE in 32 cases (86 percent).",
"   </p>",
"   <p>",
"    In our center, ultrasonography has served as a very useful tool in conjunction with clinical assessment and electrodiagnostic testing, especially in the setting of non-localizing electrodiagnostic studies, severe pain that might indicate a mass or compressive lesion, or in the case of trauma.",
"   </p>",
"   <p>",
"    Both MRI and ultrasound are also useful for suspected ulnar neuropathy at the wrist, particularly in examining for the presence of ganglia or cysts resulting in external compression of the nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19484231\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of UNE is largely unknown, and the available data are sparse. This is not surprising given the complexity of case definition, lack of standardized outcomes, and variable electrodiagnostic approaches used. Knowledge of the natural history is crucial, however, when considering the relative merits of various conservative treatments and surgery.",
"   </p>",
"   <p>",
"    The outcome with nonoperative management of UNE may depend upon the clinical severity of the condition at presentation. This conclusion is suggested by the results of a prospective study of conservative treatment of UNE for 128 patients, including 43 with bilateral involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/45\">",
"     45",
"    </a>",
"    ]. At a mean follow-up of 59 months, a successful outcome (defined as not having surgical treatment for UNE) for patients with mild, moderate, and severe presentations was reported for 89, 67, and 38 percent respectively, and the differences between these groups were statistically significant. One weakness of this study was the limited use of electrodiagnostic tests, which were completed at baseline in only a portion of subjects and were not part of the longitudinal assessment. Moreover, these data may be most applicable to patients referred for surgery, who probably represent a more severe end of the clinical spectrum. Thus, the results may not be generalizable to all patients with UNE.",
"   </p>",
"   <p>",
"    One retrospective study followed 22 patients who did not have surgical treatment for UNE involving 24 affected arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/46\">",
"     46",
"    </a>",
"    ]. Outcome assessment consisted of either telephone interview (13 affected arms) or complete clinical and electrodiagnostic re-evaluation (11 affected arms). At a mean follow-up of 13 months, the outcome was considered improved, unchanged, or worse for 12, 7, and 5 affected arms, respectively. The strength of this study is limited by methodologic issues that include small patient numbers and outcome assessment based entirely upon subjective reporting for approximately one-half of the subjects. In this regard, the same investigators had previously shown poor correlation between subjective symptoms and electrodiagnostic criteria for UNE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26073200\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, clinical experience suggests that patients with milder presentations of ulnar neuropathy who typically present with intermittent sensory symptoms and electrodiagnostic features of conduction slowing across the elbow often improve with conservative measures or remain stable over years. In all probability, many such patients do not seek medical attention for these symptoms. Those with persistent sensory loss and weakness without wasting often present acutely (sometimes with a milder pre-existing history of intermittent symptoms) and commonly have features of both conduction block and slowing on electrodiagnostic testing. This group often improves over the course of three to six months, based upon clinical and electrodiagnostic measures. Those with persistent symptoms of weakness and numbness beyond six months should be referred for consideration of surgical intervention.",
"   </p>",
"   <p>",
"    The management of ulnar neuropathy at the wrist is directed by the results of the clinical scenario and imaging. Patients with traumatic causes or with evidence of extrinsic or intrinsic neural compression should be referred for consideration of surgical treatment.",
"   </p>",
"   <p>",
"    Patients with severe weakness, wasting, and persistent sensory loss due to ulnar neuropathy at the elbow or wrist will show evidence of axonal injury on electrodiagnostic testing. In younger patients, or when the presentation is acute (less than six months) strong consideration should be given to surgical referral. However, for very elderly or medically unwell patients, and for patients with chronic (two years or longer) severe involvement, the benefit of surgical intervention is particularly doubtful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626065\">",
"    <span class=\"h2\">",
"     Conservative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest conservative treatment for patients with mild to moderate ulnar neuropathy who have intermittent or persistent sensory loss and weakness without wasting. In addition, we suggest conservative treatment rather than surgery as the initial treatment for patients who have moderate to severe but stable ulnar neuropathy of less than six months duration.",
"   </p>",
"   <p>",
"    Few prospective studies have evaluated any of the specific conservative treatments for UNE, and only one relevant randomized trial was identified in a systematic review updated in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/48\">",
"     48",
"    </a>",
"    ]. In that assessor-blind controlled trial, 70 patients with mild or moderate symptoms of cubital tunnel syndrome were randomly assigned to night splinting, nerve gliding, or control groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/49\">",
"     49",
"    </a>",
"    ]. All groups received written information regarding avoidance of movements and positions that provoke symptoms of ulnar neuropathy. There were no significant differences among the groups in any of the outcome measures.",
"   </p>",
"   <p>",
"    It is generally recommended that patients with ulnar neuropathy should avoid leaning on the elbows when seated or driving and should avoid prolonged elbow flexion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/45\">",
"     45",
"    </a>",
"    ]. Practical suggestions include using the other hand or a headset when on the telephone and avoiding sitting with the arms crossed. The use of a soft foam elbow pad may reduce inadvertent compression of the ulnar nerve at the elbow. We often recommend that patients wrap the affected elbow with a towel at night to limit flexion, since a towel wrap is usually better tolerated than more rigid braces. These simple measures often result in improvement of milder intermittent symptoms and can aid in resolution of those with moderate presentations (eg, conduction block on electrodiagnostic testing).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26073215\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest surgical treatment with ulnar nerve decompression or transposition rather than conservative therapy for patients with convincing clinical and electrophysiologic evidence of moderate to severe ulnar neuropathy at the elbow who have persistent weakness and numbness beyond six months that is refractory to conservative therapy, and for those who have moderate to severe progressive symptoms and signs of less than six months duration despite conservative measures.",
"   </p>",
"   <p>",
"    The two main categories of operation currently performed for UNE are in situ decompression of the ulnar nerve and ulnar transposition. Simple decompression is usually performed by cutting the flexor carpi ulnaris aponeurosis (the humeroulnar arcade) to decompress the ulnar nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/27\">",
"     27",
"    </a>",
"    ]. Transposition of the ulnar nerve can be achieved by first slitting the humeroulnar arcade, mobilizing the ulnar nerve from the retrocondylar groove, and then moving the nerve anteriorly. A third surgical procedure, medial epicondylectomy, is performed by removing the humeral medial epicondyle after making an incision in the humeroulnar arcade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal surgical technique for the treatment of UNE remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], other than in the setting of significant skeletal deformity or trauma, where transposition or medial epicondylectomy are generally accepted. There is only limited clinical trial evidence to support one approach versus the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/48\">",
"     48",
"    </a>",
"    ], and the choice of procedure largely has been based upon the personal experience and preference of the surgeon. In addition, there are no trials comparing surgical intervention with nonoperative conservative management or sham surgery for UNE.",
"   </p>",
"   <p>",
"    Most of the available data suggest that ulnar nerve decompression and transposition result in similar clinical outcomes, though transposition may be hampered by higher rates of complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis published in 2008 evaluated 10 studies comparing decompression and transposition for UNE, including two randomized trials and eight nonrandomized and largely retrospective observational reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/53\">",
"       53",
"      </a>",
"      ]. There were a total of 449 ulnar nerve decompression and 457 ulnar transposition procedures. The number of patients that improved with decompression and transposition was similar (320 and 335 [71 and 73 percent]), and analysis of the pooled data showed no statistically significant difference for improvement of symptoms with decompression versus transposition (odds ratio 0.75, 95% CI 0.54-1.04). However, the strength of the findings was limited by inconsistent evaluation and reporting of preoperative status and by the lack of a standard method for postoperative outcome assessment among the included studies.",
"     </li>",
"     <li>",
"      The largest controlled trial included in the meta-analysis randomly assigned 150 patients with idiopathic UNE to simple decompression or anterior subcutaneous transposition and found no significant difference in outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/54\">",
"       54",
"      </a>",
"      ]. However, the complication rate was significantly higher in the transposition group compared with the decompression group (31 versus 10 percent). These results were independent of duration and severity of the presentation and the presence of ulnar nerve subluxation.",
"     </li>",
"     <li>",
"      The second randomized trial included in the meta-analysis evaluated 44 patients and reported that clinical outcomes were similar for both decompression and submuscular transposition, regardless of severity at presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/55\">",
"       55",
"      </a>",
"      ]. However, three deep wound infections requiring hospitalization occurred in the transposition group, versus none in the decompression group.",
"     </li>",
"     <li>",
"      Another trial, not included in the meta-analysis, assigned 70 successive patients with severe UNE to either simple decompression or submuscular anterior transposition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/56\">",
"       56",
"      </a>",
"      ]. At six months after surgery, both treatment groups had similar clinical and electrodiagnostic outcomes with no major complications in either group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There appears to be growing support for simple in situ decompression for idiopathic UNE, in part because there is a seemingly higher complication rate with transposition, and in part because simple decompression is a faster procedure that is technically less demanding than transposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/12/38089/abstract/56\">",
"     56",
"    </a>",
"    ]. However, there are surgeons who continue to favor transposition based upon experience and training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26073192\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common site of focal ulnar nerve entrapment or compression is at the elbow, followed by the wrist. (See",
"      <a class=\"local\" href=\"#H19484189\">",
"       'Anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19484196\">",
"       'Sites of ulnar nerve lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ulnar lesions at the elbow typically present with numbness and tingling in the fourth and fifth digits, elbow pain, nocturnal awakening, and worsening of symptoms with repeated elbow",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wrist flexion. Ulnar lesions at the wrist typically present with hand weakness and atrophy, loss of dexterity, and variable sensory involvement. (See",
"      <a class=\"local\" href=\"#H19484203\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H87963056\">",
"       'Ulnar neuropathy at the elbow'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H87963063\">",
"       'Ulnar neuropathy at the wrist'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When suspected on the basis of clinical symptoms or signs, the diagnosis of ulnar neuropathy can be confirmed in most cases by electrodiagnostic testing. When electrodiagnosis is not able to localize the site of injury, imaging is often helpful. There are a number of provocative maneuvers for ulnar neuropathy, but the sensitivity and specificity of these maneuvers are suboptimal. (See",
"      <a class=\"local\" href=\"#H19485578\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of ulnar neuropathy includes proximal lesions of the C8 or T1 roots and the lower",
"      <span class=\"nowrap\">",
"       trunk/medial",
"      </span>",
"      cord of the brachial plexus, and central nervous system lesions (rarely) such as motor neuron disease, cervical syringomyelia, and small subcortical infarctions. (See",
"      <a class=\"local\" href=\"#H26073279\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrodiagnostic testing, typically involving nerve conduction studies and sometimes needle electromyography, is a standard part of the evaluation for ulnar neuropathy. In addition, both MRI and ultrasonography are useful diagnostic tests for ulnar neuropathy at the elbow. (See",
"      <a class=\"local\" href=\"#H19484217\">",
"       'Electrodiagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19484224\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of UNE is largely unknown, and the available data are sparse. (See",
"      <a class=\"local\" href=\"#H19484231\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild to moderate ulnar neuropathy who have intermittent or persistent sensory loss and weakness without wasting, we suggest conservative management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In addition, for patients who have moderate to severe but stable ulnar neuropathy of less than six months duration, we suggest conservative treatment rather than surgery as the initial treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26073200\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H626065\">",
"       'Conservative treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with convincing clinical and electrodiagnostic evidence of moderate to severe ulnar neuropathy at the elbow who have persistent weakness and numbness beyond six months that is refractory to conservative therapy, or those who have moderate to severe progressive symptoms and signs of less than six months duration despite conservative measures, we suggest surgical treatment with ulnar nerve decompression or transposition rather than conservative therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, for very elderly or medically unwell patients, and for patients with chronic (two years or longer) severe involvement, the benefit of surgical intervention is doubtful. The choice between decompression and transposition for ulnar neuropathy at the elbow depends mainly on the experience and preference of the surgeon. (See",
"      <a class=\"local\" href=\"#H26073200\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26073215\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/1\">",
"      Campbell WW. Diagnosis and management of common compression and entrapment neuropathies. Neurol Clin 1997; 15:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/2\">",
"      Campbell WW, Pridgeon RM, Riaz G, et al. Variations in anatomy of the ulnar nerve at the cubital tunnel: pitfalls in the diagnosis of ulnar neuropathy at the elbow. Muscle Nerve 1991; 14:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/3\">",
"      Bradshaw DY, Shefner JM. Ulnar neuropathy at the elbow. Neurol Clin 1999; 17:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/4\">",
"      Werner CO, Ohlin P, Elmqvist D. Pressures recorded in ulnar neuropathy. Acta Orthop Scand 1985; 56:404.",
"     </a>",
"    </li>",
"    <li>",
"     Panas P. Sur une cause peu connue de paralysie du nerf cubital, 2, Archives Generales de Medecine, 1878. Vol VII Serie.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/6\">",
"      Broca A, Mouchet A. Complications nerveuses des fractures de l'extr&eacute;mit&eacute; inf&eacute;rieure de l'hum&eacute;rus. Revue de Chirurgie 1899; 19:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/7\">",
"      Buzzard EF. Some varieties of toxic and traumatic ulnar neuritis. Lancet 1922; 199:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/8\">",
"      FEINDEL W, STRATFORD J. Cubital tunnel compression in tardy ulnar palsy. Can Med Assoc J 1958; 78:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/9\">",
"      Jones HR Jr. Pizza cutter's palsy. N Engl J Med 1988; 319:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/10\">",
"      Burnham RS, Steadward RD. Upper extremity peripheral nerve entrapments among wheelchair athletes: prevalence, location, and risk factors. Arch Phys Med Rehabil 1994; 75:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/11\">",
"      Akuthota V, Plastaras C, Lindberg K, et al. The effect of long-distance bicycling on ulnar and median nerves: an electrophysiologic evaluation of cyclist palsy. Am J Sports Med 2005; 33:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/12\">",
"      Padua L, Insola A, LoMonaco M, et al. A case of Guyon syndrome with neuroapraxic block resolved after surgical decompression. Electroencephalogr Clin Neurophysiol 1998; 109:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/13\">",
"      Richmond DR. Handlebar problems in bicycling. Clin Sports Med 1994; 13:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/14\">",
"      Foucher G, Berard V, Snider G, et al. Distal ulnar nerve entrapment due to tumors of Guyon's canal. A series of ten cases. Handchir Mikrochir Plast Chir 1993; 25:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/15\">",
"      Bartels RH, Grotenhuis JA, Kauer JM. The arcade of Struthers: an anatomical study. Acta Neurochir (Wien) 2003; 145:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/16\">",
"      Ochiai N, Hayashi T, Ninomiya S. High ulnar nerve palsy caused by the arcade of Struthers. J Hand Surg Br 1992; 17:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/17\">",
"      Ochiai N, Honmo J, Tsujino A, Nisiura Y. Electrodiagnosis in entrapment neuropathy by the arcade of Struthers. Clin Orthop Relat Res 2000; :129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/18\">",
"      Posner MA. Compressive ulnar neuropathies at the elbow: I. Etiology and diagnosis. J Am Acad Orthop Surg 1998; 6:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/19\">",
"      Nakajima M, Ono N, Kojima T, Kusunose K. Ulnar entrapment neuropathy along the medial intermuscular septum in the midarm. Muscle Nerve 2009; 39:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/20\">",
"      Mondelli M, Giannini F, Ballerini M, et al. Incidence of ulnar neuropathy at the elbow in the province of Siena (Italy). J Neurol Sci 2005; 234:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/21\">",
"      Latinovic R, Gulliford MC, Hughes RA. Incidence of common compressive neuropathies in primary care. J Neurol Neurosurg Psychiatry 2006; 77:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/22\">",
"      Bartels RH, Verbeek AL. Risk factors for ulnar nerve compression at the elbow: a case control study. Acta Neurochir (Wien) 2007; 149:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/23\">",
"      Richardson JK, Green DF, Jamieson SC, Valentin FC. Gender, body mass and age as risk factors for ulnar mononeuropathy at the elbow. Muscle Nerve 2001; 24:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/24\">",
"      Stewart JD. The variable clinical manifestations of ulnar neuropathies at the elbow. J Neurol Neurosurg Psychiatry 1987; 50:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/25\">",
"      Beekman R, Schreuder AH, Rozeman CA, et al. The diagnostic value of provocative clinical tests in ulnar neuropathy at the elbow is marginal. J Neurol Neurosurg Psychiatry 2009; 80:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/26\">",
"      Novak CB, Lee GW, Mackinnon SE, Lay L. Provocative testing for cubital tunnel syndrome. J Hand Surg Am 1994; 19:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/27\">",
"      Stewart J. Ulnar neuropathies: where, why, and what to do? Pract Neurol 2006; 6:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/28\">",
"      American Association of Electrodiagnostic Medicine, Campbell WW. Guidelines in electrodiagnostic medicine. Practice parameter for electrodiagnostic studies in ulnar neuropathy at the elbow. Muscle Nerve Suppl 1999; 8:S171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/29\">",
"      Payan J. Electrophysiological localization of ulnar nerve lesions. J Neurol Neurosurg Psychiatry 1969; 32:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/30\">",
"      Campbell WW. Ulnar neuropathy at the elbow. Muscle Nerve 2000; 23:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/31\">",
"      Campbell WW, Pridgeon RM, Sahni KS. Short segment incremental studies in the evaluation of ulnar neuropathy at the elbow. Muscle Nerve 1992; 15:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/32\">",
"      Visser LH, Beekman R, Franssen H. Short-segment nerve conduction studies in ulnar neuropathy at the elbow. Muscle Nerve 2005; 31:331.",
"     </a>",
"    </li>",
"    <li>",
"     Preston DC, Shapiro BE. Ulnar neuropathy. In: Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, Butterworth-Heinemann, Boston 1998. p.265.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/34\">",
"      Beekman R, Van Der Plas JP, Uitdehaag BM, et al. Clinical, electrodiagnostic, and sonographic studies in ulnar neuropathy at the elbow. Muscle Nerve 2004; 30:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/35\">",
"      Kothari MJ, Heistand M, Rutkove SB. Three ulnar nerve conduction studies in patients with ulnar neuropathy at the elbow. Arch Phys Med Rehabil 1998; 79:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/36\">",
"      Raynor EM, Shefner JM, Preston DC, Logigian EL. Sensory and mixed nerve conduction studies in the evaluation of ulnar neuropathy at the elbow. Muscle Nerve 1994; 17:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/37\">",
"      Filler AG, Maravilla KR, Tsuruda JS. MR neurography and muscle MR imaging for image diagnosis of disorders affecting the peripheral nerves and musculature. Neurol Clin 2004; 22:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/38\">",
"      Andreisek G, Crook DW, Burg D, et al. Peripheral neuropathies of the median, radial, and ulnar nerves: MR imaging features. Radiographics 2006; 26:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/39\">",
"      Koenig RW, Pedro MT, Heinen CP, et al. High-resolution ultrasonography in evaluating peripheral nerve entrapment and trauma. Neurosurg Focus 2009; 26:E13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/40\">",
"      B&auml;umer P, Dombert T, Staub F, et al. Ulnar neuropathy at the elbow: MR neurography--nerve T2 signal increase and caliber. Radiology 2011; 260:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/41\">",
"      Beekman R, Visser LH, Verhagen WI. Ultrasonography in ulnar neuropathy at the elbow: a critical review. Muscle Nerve 2011; 43:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/42\">",
"      Britz GW, Haynor DR, Kuntz C, et al. Ulnar nerve entrapment at the elbow: correlation of magnetic resonance imaging, clinical, electrodiagnostic, and intraoperative findings. Neurosurgery 1996; 38:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/43\">",
"      Vucic S, Cordato DJ, Yiannikas C, et al. Utility of magnetic resonance imaging in diagnosing ulnar neuropathy at the elbow. Clin Neurophysiol 2006; 117:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/44\">",
"      Beekman R, Schoemaker MC, Van Der Plas JP, et al. Diagnostic value of high-resolution sonography in ulnar neuropathy at the elbow. Neurology 2004; 62:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/45\">",
"      Dellon AL, Hament W, Gittelshon A. Nonoperative management of cubital tunnel syndrome: an 8-year prospective study. Neurology 1993; 43:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/46\">",
"      Padua L, Aprile I, Caliandro P, et al. Natural history of ulnar entrapment at elbow. Clin Neurophysiol 2002; 113:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/47\">",
"      Padua L, Aprile I, Mazza O, et al. Neurophysiological classification of ulnar entrapment across the elbow. Neurol Sci 2001; 22:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/48\">",
"      Caliandro P, La Torre G, Padua R, et al. Treatment for ulnar neuropathy at the elbow. Cochrane Database Syst Rev 2012; 7:CD006839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/49\">",
"      Svernl&ouml;v B, Larsson M, Rehn K, Adolfsson L. Conservative treatment of the cubital tunnel syndrome. J Hand Surg Eur Vol 2009; 34:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/50\">",
"      Craven PR Jr, Green DP. Cubital tunnel syndrome. Treatment by medial epicondylectomy. J Bone Joint Surg Am 1980; 62:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/51\">",
"      Mowlavi A, Andrews K, Lille S, et al. The management of cubital tunnel syndrome: a meta-analysis of clinical studies. Plast Reconstr Surg 2000; 106:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/52\">",
"      Bartels RH, Menovsky T, Van Overbeeke JJ, Verhagen WI. Surgical management of ulnar nerve compression at the elbow: an analysis of the literature. J Neurosurg 1998; 89:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/53\">",
"      Macadam SA, Gandhi R, Bezuhly M, Lefaivre KA. Simple decompression versus anterior subcutaneous and submuscular transposition of the ulnar nerve for cubital tunnel syndrome: a meta-analysis. J Hand Surg Am 2008; 33:1314.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/54\">",
"      Bartels RH, Verhagen WI, van der Wilt GJ, et al. Prospective randomized controlled study comparing simple decompression versus anterior subcutaneous transposition for idiopathic neuropathy of the ulnar nerve at the elbow: Part 1. Neurosurgery 2005; 56:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/55\">",
"      Biggs M, Curtis JA. Randomized, prospective study comparing ulnar neurolysis in situ with submuscular transposition. Neurosurgery 2006; 58:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/12/38089/abstract/56\">",
"      Gervasio O, Gambardella G, Zaccone C, Branca D. Simple decompression versus anterior submuscular transposition of the ulnar nerve in severe cubital tunnel syndrome: a prospective randomized study. Neurosurgery 2005; 56:108.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14172 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38089=[""].join("\n");
var outline_f37_12_38089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26073192\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19484182\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19484189\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19484196\">",
"      Sites of ulnar nerve lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26073271\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19484203\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87963056\">",
"      Ulnar neuropathy at the elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87963063\">",
"      Ulnar neuropathy at the wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19485578\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26073279\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170956430\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170956483\">",
"      Provocative tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19484217\">",
"      Electrodiagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H529565\">",
"      - Ulnar neuropathy at the elbow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H529572\">",
"      - Ulnar neuropathy at the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19484224\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19484231\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26073200\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626065\">",
"      Conservative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26073215\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26073192\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14172\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14172|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/25/35222\" title=\"figure 1\">",
"      Trunks and cords of the brachial plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/56/23428\" title=\"figure 2\">",
"      Ulnar nerve distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/62/34785\" title=\"figure 3\">",
"      Anatomy of the ulnar nerve at the elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/56/24448\" title=\"figure 4\">",
"      Cutaneous sensory distribution of the ulnar nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/0/15364\" title=\"figure 5\">",
"      Major branches of the ulnar nerve at the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/2/20514\" title=\"figure 6\">",
"      Effect of elbow flexion on the ulnar nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/37/6751\" title=\"figure 7\">",
"      Conduction block and slowing across the elbow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14172|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/36/23107\" title=\"picture 1\">",
"      Claw hand deformity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_12_38090="Atypical carcinoid necrosis";
var content_f37_12_38090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59297%7EPULM%2F81703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59297%7EPULM%2F81703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical pulmonary carcinoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-power photomicrograph of an atypical pulmonary carcinoid tumor shows focal necrosis (arrows) within a nest of tumor cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical carcinoid tumor of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph showing an atypical carcinoid tumor of the lung. The tumor shows a growth pattern reminiscent of that seen in carcinoid tumors of the more usual type, but differs in that there is associated tumor necrosis as seen in the upper portion of the photomicrograph (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38090=[""].join("\n");
var outline_f37_12_38090=null;
var title_f37_12_38091="Radionuclide yields fission";
var content_f37_12_38091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Yields of radionuclides from nuclear fission",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Radionuclide",
"       </td>",
"       <td class=\"subtitle1\">",
"        Half-life",
"       </td>",
"       <td class=\"subtitle1\">",
"        Yield (MCi per megaton)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodine-131",
"       </td>",
"       <td>",
"        8 days",
"       </td>",
"       <td>",
"        125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerium-131",
"       </td>",
"       <td>",
"        1 year",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zirconium-95",
"       </td>",
"       <td>",
"        65 days",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strontium-89",
"       </td>",
"       <td>",
"        53 days",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ruthenium-103",
"       </td>",
"       <td>",
"        40 days",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerium-144",
"       </td>",
"       <td>",
"        33 days",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ruthenium-106",
"       </td>",
"       <td>",
"        1 year",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cesium-137",
"       </td>",
"       <td>",
"        30 years",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strontium-90",
"       </td>",
"       <td>",
"        28 years",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table shows some of the most important radionuclides produced during explosion of a nuclear fission device. Yields are expressed as millicuries (MCi) per megaton.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From The Medical NBC Battlebook United States Army CHPPM, Technical Guide 244, August, 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38091=[""].join("\n");
var outline_f37_12_38091=null;
var title_f37_12_38092="Diseases with impaired taste";
var content_f37_12_38092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disease and exposures that affect the sense of taste",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Disease",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mechanism/comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bell's palsy",
"      </td>",
"      <td>",
"       72 percent of patients with unilateral disease recover taste in 12 to 14 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bone marrow transplantation",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cancer",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Crohn's disease",
"      </td>",
"      <td>",
"       Zinc deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic chromium exposure",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cirrhosis of the liver",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Depression",
"      </td>",
"      <td>",
"       Zinc deficiency from poor dietary intake?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes mellitus with peripheral neuropathy",
"      </td>",
"      <td>",
"       Hypogeusia to sweetness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gingivitis",
"      </td>",
"      <td>",
"       Salty dysgeusia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Guillain-Barre syndrome",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hemodialysis",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herpes simplex infection",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Human immunodeficiency virus infection",
"      </td>",
"      <td>",
"       Malnutrition, a-interferon",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperaldosteronism",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Influenza",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lead or copper poisoning",
"      </td>",
"      <td>",
"       Metallic dysgeusia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meningitis",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Migraine headache",
"      </td>",
"      <td>",
"       Gustatory hallucinations?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiple sclerosis",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parkinson disease",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pernicious anemia (vitamin B12)",
"      </td>",
"      <td>",
"       Taste bud degeneration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation treatment to head and neck",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recent dental procedure",
"      </td>",
"      <td>",
"       Dysgeusia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sj&ouml;gren's syndrome",
"      </td>",
"      <td>",
"       Hypogeusia and xerostomia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tonsillectomy",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thrush",
"      </td>",
"      <td>",
"       Dysgeusia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Zinc deficiency (disassociated taste disorder)",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Ackerman, BH, Kasbekar, N. Pharmacotherapy 1997; 17:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38092=[""].join("\n");
var outline_f37_12_38092=null;
var title_f37_12_38093="Ventilation lactate exercise";
var content_f37_12_38093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ventilatory and blood lactate response to exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ventilatory and blood lactate response to exercise as a function of oxygen uptake (VO2) The anaerobic threshold (AT) indicates the onset of significant anaerobic metabolism and the production of lactate, which occurs at approximately 50 to 60 percent of VO2max.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38093=[""].join("\n");
var outline_f37_12_38093=null;
var title_f37_12_38094="CMT types 1 through 3";
var content_f37_12_38094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72688%7EPEDS%2F52711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72688%7EPEDS%2F52711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetics of CMT1, CTM2, and CMT3",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        CMT1",
"       </td>",
"       <td>",
"        Onset in first or second decade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1A",
"       </td>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2-p1",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Motor symptoms predominate (clumsy walking)",
"        </p>",
"        <p>",
"         Gradual loss of proprioception and vibration",
"        </p>",
"        <p>",
"         Ambulation usually maintained",
"        </p>",
"        <p>",
"         Normal life expectancy",
"        </p>",
"        <p>",
"         Palpable enlargement of the peripheral nerves",
"        </p>",
"        <p>",
"         NCV slowed to &lt;60 percent normal",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1B",
"       </td>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1C",
"       </td>",
"       <td>",
"        LITAF",
"       </td>",
"       <td>",
"        16p.13.1-p12.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1D",
"       </td>",
"       <td>",
"        EGR2",
"       </td>",
"       <td>",
"        10q21.1-q22.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1E",
"       </td>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2-p1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1F",
"       </td>",
"       <td>",
"        NEFL",
"       </td>",
"       <td>",
"        8p21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Roussy-Levy",
"       </td>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         CTM1 features plus:",
"        </p>",
"        <p>",
"         Postural tremor and gait ataxia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMTX1",
"       </td>",
"       <td>",
"        GJB1",
"       </td>",
"       <td>",
"        Xq13.1",
"       </td>",
"       <td>",
"        <p>",
"         CMT1 features plus:",
"        </p>",
"        <p>",
"         Symptoms more prominent in males",
"        </p>",
"        <p>",
"         Symptomatic in second decade",
"        </p>",
"        <p>",
"         Loss of ankle reflexes",
"        </p>",
"        <p>",
"         NCV moderately slowed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        CMT2",
"       </td>",
"       <td>",
"        Onset in second or third decade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CTM2A",
"       </td>",
"       <td>",
"        MFN2",
"       </td>",
"       <td>",
"        1p36.2",
"       </td>",
"       <td rowspan=\"10\">",
"        Sensory symptoms predominate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CTM2B",
"       </td>",
"       <td>",
"        RAB7",
"       </td>",
"       <td>",
"        3q21.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2C",
"       </td>",
"       <td>",
"        TRPV4",
"       </td>",
"       <td>",
"        12q24.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CTM2D",
"       </td>",
"       <td>",
"        GARS",
"       </td>",
"       <td>",
"        7p15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2E",
"       </td>",
"       <td>",
"        NEFL",
"       </td>",
"       <td>",
"        8p",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2F",
"       </td>",
"       <td>",
"        HSPB1",
"       </td>",
"       <td>",
"        7q11.23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2G",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        12q12-q13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2I",
"       </td>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2K",
"       </td>",
"       <td>",
"        GDAP1",
"       </td>",
"       <td>",
"        8q13-q21.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2L",
"       </td>",
"       <td>",
"        HSPB8",
"       </td>",
"       <td>",
"        12q24.23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Early onset",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        <p>",
"         Onset before age 5 years",
"        </p>",
"        <p>",
"         Rapid progression of weakness below the knee",
"        </p>",
"        <p>",
"         Loss of ambulation by mid-teens",
"        </p>",
"        <p>",
"         NCV normal or mildly reduced",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        CMT3",
"       </td>",
"       <td>",
"        Severe, early onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Dejerine-Sottas syndrome",
"       </td>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2-p1",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Hypotonia in early infancy",
"        </p>",
"        <p>",
"         Delayed motor development",
"        </p>",
"        <p>",
"         Initial sensory loss and distal weakness",
"        </p>",
"        <p>",
"         Ataxia",
"        </p>",
"        <p>",
"         NCV profoundly slowed (10m/sec)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGR2",
"       </td>",
"       <td>",
"        10q21.1-q22.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Congenital hypomyelinating neuropathy",
"       </td>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2-p1",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Profound hypotonia and contractures at birth",
"        </p>",
"        <p>",
"         Feeding difficulties",
"        </p>",
"        <p>",
"         Respiratory distress",
"        </p>",
"        <p>",
"         Death in infancy",
"        </p>",
"        <p>",
"         NCV extremely slowed or absent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGR2",
"       </td>",
"       <td>",
"        10q21.1-q22.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of CMT4, CMT5, CMT6, and CMT7",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        CMT4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4A",
"       </td>",
"       <td>",
"        GDAP1",
"       </td>",
"       <td>",
"        8q13-q21.1",
"       </td>",
"       <td>",
"        <p>",
"         Onset in early childhood",
"        </p>",
"        <p>",
"         Distal weakness",
"        </p>",
"        <p>",
"         Mild sensory loss",
"        </p>",
"        <p>",
"         Rapidly progressive",
"        </p>",
"        <p>",
"         Incapacity in first decade",
"        </p>",
"        <p>",
"         NCV moderately reduced",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4B1",
"       </td>",
"       <td>",
"        MTMR2",
"       </td>",
"       <td>",
"        11q22-23",
"       </td>",
"       <td>",
"        <p>",
"         Onset at age 2 to 4 years",
"        </p>",
"        <p>",
"         Distal and proximal weakness",
"        </p>",
"        <p>",
"         Moderate sensory loss",
"        </p>",
"        <p>",
"         Frequent involvement of cranial nerves",
"        </p>",
"        <p>",
"         NCV slowed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4B2",
"       </td>",
"       <td>",
"        CMT4B2",
"       </td>",
"       <td>",
"        11p15",
"       </td>",
"       <td>",
"        <p>",
"         Onset in first two decades",
"        </p>",
"        <p>",
"         Initial distal weakness",
"        </p>",
"        <p>",
"         Proximal weakness after several years",
"        </p>",
"        <p>",
"         NCV slowed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4C",
"       </td>",
"       <td>",
"        SH3TC2",
"       </td>",
"       <td>",
"        5q32",
"       </td>",
"       <td>",
"        <p>",
"         Severe spinal deformities and weakness",
"        </p>",
"        <p>",
"         Onset in childhood and adolescence",
"        </p>",
"        <p>",
"         NCV slowed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4D",
"       </td>",
"       <td>",
"        NDRG1",
"       </td>",
"       <td>",
"        8q24.3",
"       </td>",
"       <td>",
"        <p>",
"         Early onset neuropathy",
"        </p>",
"        <p>",
"         Muscle weakness and wasting",
"        </p>",
"        <p>",
"         Skeletal deformities",
"        </p>",
"        <p>",
"         Sensory loss",
"        </p>",
"        <p>",
"         Neural deafness in second or third decade",
"        </p>",
"        <p>",
"         NCV severely reduced",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4E",
"       </td>",
"       <td>",
"        EGR2",
"       </td>",
"       <td>",
"        10q21.1-22.1",
"       </td>",
"       <td>",
"        Distal weakness at birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4F",
"       </td>",
"       <td>",
"        PRX",
"       </td>",
"       <td>",
"        19q13.1-13.2",
"       </td>",
"       <td>",
"        <p>",
"         Onset in early childhood",
"        </p>",
"        <p>",
"         Distal muscle weakness",
"        </p>",
"        <p>",
"         Severe sensory loss",
"        </p>",
"        <p>",
"         Absent sensory and motor evoked response on NCV",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4H",
"       </td>",
"       <td>",
"        FGD4",
"       </td>",
"       <td>",
"        12p11.2",
"       </td>",
"       <td>",
"        <p>",
"         Severe demyelinating neuropathy",
"        </p>",
"        <p>",
"         Unsteady gait",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4J",
"       </td>",
"       <td>",
"        FIG4",
"       </td>",
"       <td>",
"        6q21",
"       </td>",
"       <td>",
"        <p>",
"         Childhood or adult onset",
"        </p>",
"        <p>",
"         Widespread denervation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         CMT5",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Spastic paraparesis",
"        </p>",
"        <p>",
"         Sensory neuropathy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         CTM6",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Optic atrophy",
"        </p>",
"        <p>",
"         Motor sensory neuropathy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         CMT7",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Retinitis pigmentosa",
"        </p>",
"        <p>",
"         Motor sensory neuropathy",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38094=[""].join("\n");
var outline_f37_12_38094=null;
var title_f37_12_38095="Mastocytoma solitary";
var content_f37_12_38095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solitary mastocytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solitary mastocytoma presents as a pink-yellowish plaque that typically urticates and becomes erythematous after rubbing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Kate P&uuml;ttgen.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_12_38095=[""].join("\n");
var outline_f37_12_38095=null;
              